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A B S T R A C T
Background
Asthma is a common long-term breathing condition that affects approximately 300 million people worldwide. People with asthma
may experience short-term worsening of their asthma symptoms; these episodes are often known as ‘exacerbations’, ‘flare-ups’, ‘attacks’
or ’acute asthma’. Oral steroids, which have a potent anti-inflammatory effect, are recommended for all but the most mild asthma
exacerbations; they should be initiated promptly. The most often prescribed oral steroids are prednisolone and dexamethasone, but
current guidelines on dosing vary between countries, and often among different guideline producers within the same country. Despite
their proven efficacy, use of steroids needs to be balanced against their potential to cause important adverse events. Evidence is somewhat
limited regarding optimal dosing of oral steroids for asthma exacerbations to maximise recovery while minimising potential side effects,
which is the topic of this review.
Objectives
To assess the efficacy and safety of any dose or duration of oral steroids versus any other dose or duration of oral steroids for adults and
children with an asthma exacerbation.
Search methods
We identified trials from the Cochrane Airways Group Specialised Register (CAGR), ClinicalTrials.gov (www.ClinicalTrials.gov), the
World Health Organization (WHO) trials portal (www.who.int/ictrp/en/) and reference lists of all primary studies and review articles.
This search was up to date as of April 2016.
Selection criteria
We included parallel randomised controlled trials (RCTs), irrespective of blinding or duration, that evaluated one dose or duration of
oral steroid versus any other dose or duration, for management of asthma exacerbations. We included studies involving both adults
and children with asthma of any severity, in which investigators analysed adults and children separately. We allowed any other co-
intervention in the management of an asthma exacerbation, provided it was not part of the randomised treatment. We included studies
reported as full text, those published as abstract only and unpublished data.
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Data collection and analysis
Two review authors independently screened the search results for included trials, extracted numerical data and assessed risk of bias; all
data were cross-checked for accuracy. We resolved disagreements by discussion with the third review author or with an external advisor.
We analysed dichotomous data as odds ratios (ORs) or risk differences (RDs) using study participants as the unit of analysis; we
analysed continuous data as mean differences (MDs). We used a random-effects model, and we carried out a fixed-effect analysis if we
detected statistical heterogeneity. We rated all outcomes using the GRADE (Grades of Recommendation, Assessment, Development
and Evaluation) system and presented results in ’Summary of findings’ tables.
Main results
We included 18 studies that randomised a total of 2438 participants - both adults and children - and performed comparisons of interest.
Included studies assessed higher versus lower doses of prednisolone (n = 4); longer versus shorter courses of prednisolone (n = 3) or
dexamethasone (n = 1); tapered versus non-tapered courses of prednisolone (n = 4); and prednisolone versus dexamethasone (n = 6).
Follow-up duration ranged from seven days to six months. The smallest study randomised just 15 participants, and the largest 638
(median 93). The varied interventions and outcomes reported limited the number of meaningful meta-analyses that we could perform.
For two of our primary outcomes - hospital admission and serious adverse events - events were too infrequent to permit conclusions
about the superiority of one treatment over the other, or their equivalence. Researchers in the included studies reported asthma
symptoms in different ways and rarely used validated scales, again limiting our conclusions. Secondary outcome meta-analysis was
similarly hampered by heterogeneity among interventions and outcome measures used. Overall, we found no convincing evidence of
differences in outcomes between a higher dose or longer course and a lower dose or shorter course of prednisolone or dexamethasone,
or between prednisolone and dexamethasone.
Included studies were generally of reasonable methodological quality. Review authors assessed most outcomes in the review as having
low or very low quality, meaning we are not confident in the effect estimates. The predominant reason for downgrading was imprecision,
but indirectness and risk of bias also reduced our confidence in some estimates.
Authors’ conclusions
Evidence is not strong enough to reveal whether shorter or lower-dose regimens are generally less effective than longer or higher-dose
regimens, or indeed that the latter are associated with more adverse events. Any changes recommended for current practice should be
supported by data from larger, well-designed trials. Varied study design and outcome measures limited the number of meta-analyses
that we could perform. Greater emphasis on palatability and on whether some regimens might be easier to adhere to than others could
better inform clinical decisions for individual patients.
P L A I N L A N G U A G E S U M M A R Y
Different doses and durations of oral steroids for asthma attacks
Background: People with asthma sometimes have asthma attacks, wherein their symptoms such as cough, chest tightness and difficulty
breathing become worse. Many patients with asthma attacks are treated with steroids, which are usually given as a short course of tablets
or liquid medicine. Steroids work by reducing inflammation in the airways in the lungs, but they can have side effects (e.g. reduced
growth in children, hyperactivity, nausea).
Review question:We set out to compare different doses or durations of oral steroids given to people having asthma attacks. This is an
important issue because different doses and durations of oral steroids are used for asthma attacks in different countries, and we do not
know which regimen is most likely to improve symptoms while minimising unpleasant side effects.
Study characteristics:We included 18 studies involving 2438 adults and children. Studies compared two types of steroid - prednisolone
and dexamethasone - or two different doses or durations of either drug. The smallest study included just 15 people, and the largest
638. Studies followed people for between seven days and six months to see what happened to them. The evidence presented here is
current to April 2016.
Key results: It was difficult to combine the results of studies in a useful way because investigators used a variety of doses and durations
of steroids and measured their results in different ways. Also, events such as hospital admissions and serious side effects happened very
rarely in these studies, making it difficult to tell whether longer or shorter courses or higher or lower doses are better or safer, or if
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prednisolone is generally better or worse than dexamethasone. Some studies were old and did not use steroid doses or durations used
by medical practitioners today.
Any changes to the way in which asthma attacks are currently managed with oral steroids would need to be supported by larger studies
than have been conducted so far.
Quality of the evidence: Evidence presented in this review is generally considered to be of low or very low quality, which means we are
not very sure whether the results are accurate, mostly because we have not been able to combine many studies. Some studies did not
clearly explain how trial organisers decided which people would receive which dose of steroids, and in some studies, both participants
and trial organisers knew which dose they were getting. This may have affected study results.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Adults: higher dose/ longer course compared with lower dose/ shorter course for acute asthma
Patient or population: adults with an acute exacerbat ion of asthma
Setting: inpat ient or community
Intervention: higher dose/ longer course of prednisolone
Comparison: lower dose/ shorter course of prednisolone
Duration range: 3 to 26 weeks
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with lower dose/
shorter course
Risk with higher dose/
longer course
Re-admission in fol-
low-up period
Longer vs shorter course prednisolone OR 1.35
(0.38 to 4.79)
142
(4 RCTs)
⊕⊕©©
Lowa,b
74 per 1000 97 per 1000
(29 to 275)
Asthma symptoms
Asthma severity score
Longer vs shorter course prednisolone - 44
(1 RCT)
⊕⊕©©
Lowc,d
Higher score = Worse
symptoms
Mean asthma severity
score was 2.6
Mean asthma sever-
ity score in the longer
course group was 0.7
lower (1.28 lower to 0.
12 lower)
Asthma symptoms
Complete resolut ion by
day 28
Longer vs shorter course prednisolone OR 0.55
(0.13 to 2.26)
35
(1 RCT)
⊕⊕©©
Lowb,e
412 per 1000 278 per 1000
(83 to 613)
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New exacerbation in
follow-up period
Requiring visit to
healthcare provider
Longer vs shorter course prednisolone OR 0.98
(0.17 to 5.56)
55
(2 RCTs)
⊕©©©
Very lowb,f,g111 per 1000 109 per 1000
(21 to 410)
Stable (same daily dose for 7 days) vs tapered
(tapering daily dose over 7 days) prednisolone
OR 3.56
(0.34 to 37.36)
41
(2 RCTs)
⊕©©©
Very lowb,f,g
No events were re-
ported in the tapered
arm and only 2 events
in the stable arm, so we
were unable to calcu-
late a baseline riskNo events Risk dif ference in the
stable (higher total
dose) group was 9% (0
to 26%)
New exacerbation in
follow-up period
Oral cort icosteroids
prescribed
Longer vs shorter course prednisolone OR 0.62
(0.23 to 1.68)
122
(3 RCTs)
⊕⊕©©
Lowa,b
Lederle 1987 domi-
nates this analysis, as
the event rate was
much higher than in the
other 2 studies, possi-
bly ref lect ing co-morbid
COPD in the study popu-
lat ion. Result should be
interpreted with caut ion
241 per 1000 165 per 1000 (68 to
348)
Lung function tests
FEV1% predicted
Stable (same daily dose for 7 days) vs tapered
(tapering daily dose over 7 days) prednisolone
- 41
(2 RCTs)
⊕©©©
Very lowf,g,h
Higher percentage =
Better lung funct ion
Mean FEV1% predicted
was 70.6
Mean FEV1% predicted
in the stable dose
(higher total dose) was
1.02 lower (4.62 lower
to 2.58 higher)
All adverse events Longer vs shorter course prednisolone OR 4.15
(0.94 to 18.41)
43
(1 RCT)
⊕©©©
Very lowe,i
143 per 1000 409 per 1000
(135 to 754)
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* Risk in the intervention group (and its 95% conf idence interval) is based on assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI)
CI: Conf idence interval; COPD: chronic obstruct ive pulmonary disease; FEV1: f orced expiratory volume in 1 second; OR: Odds rat io; RCT: randomised controlled trial; RR: Risk
rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to the est imate of ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of ef fect but may be substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aLederle 1987 carried a large proport ion of the analysis weight for this outcome because event rates were higher in both
groups. This may ref lect co-morbid COPD (part icipants were older and most had an extensive smoking history). Downgraded
once for indirectness
bConf idence intervals include no dif ference and an important benef it of a longer or shorter course. Downgraded once for
imprecision
cConf idence intervals excluded possible benef it of a shorter course, but the ef fect was based on only 1 study of 44 people.
Downgraded once for imprecision
dA 1-7 scale of symptom severity averaged over days 6-21 was used, making clinical benef it dif f icult to interpret. Downgraded
once for indirectness
eNeither treatment regimen used in the one study in this analysis is consistent with current internat ional guidance. Downgraded
once for indirectness
f The study contribut ing most of the analysis weight was unblinded and uncertaint ies surrounded the select ion procedure.
Downgraded once for risk of bias
gBoth trials contribut ing to the analysis used a treatment regimen that was inconsistent with current internat ional guidance.
Downgraded once for indirectness
hThe ef fect was derived f rom 2 very sim ilar studies including 41 people in total. Studies had smaller standard deviat ions than
would be expected given the sample sizes. Downgraded once for imprecision
iThe result is based on 1 small study and has wide conf idence intervals, which do not exclude the possibility of no dif ference
or an important increase in adverse events in the longer course arm, Downgraded twice for imprecision
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B A C K G R O U N D
Description of the condition
Asthma is a common long-term breathing condition that affects
approximately 300 million people worldwide and causes an es-
timated 250,000 deaths every year (WHO 2007). Between 1%
and 18% of people in different countries are affected by asthma
(GINA 2015), which is characterised by chronic airway inflam-
mation and airway hyperresponsiveness, leading to shortness of
breath, wheeze, chest tightness and cough. Symptoms are typically
worse at night and in the early morning and may vary over time
(CDC 2012; GINA 2015). Treatments are largely aimed at reduc-
ing airway smooth muscle constriction through the use of inhaled
bronchodilators (e.g. short- and long-acting beta2-agonists) and
reducing airway inflammation through the use of corticosteroids,
which usually are also inhaled (BTS/SIGN 2014).
People with asthma may experience short-term worsening of their
asthma symptoms; these episodes are known as ‘exacerbations’,
‘flare-ups’, ‘attacks’ or ’acute asthma’. Exacerbations are charac-
terised by episodes of “progressive increase in shortness of breath,
cough, wheezing, or chest tightness, or some combination of these
symptoms” (NAEPP 2007). International consensus on the def-
inition of an attack or exacerbation has not been reached, but a
working group in the USA recently suggested the definition as “a
worsening of asthma requiring the use of systemic corticosteroids
to prevent a serious outcome” (Fuhlbrigge 2012).
In the USA in 2008, more than half of adults and children with
asthma had at least one asthma exacerbation (CDC 2011). Asthma
exacerbation triggers vary fromperson topersonbut commonly in-
clude tobacco smoke, respiratory tract infection, house dust mites,
air pollution, pets and mould (CDC 2006). Depending on sever-
ity, asthma exacerbations usually require a temporary change in
the medication regimen for a person with asthma, for example,
increased use of short-acting bronchodilators such as salbutamol
and a course of systemic steroids. More severe exacerbations may
require treatment in an emergency department or admission to
the hospital (BTS/SIGN 2014).
Description of the intervention
Oral steroids are recommended for all but the most mild
asthma exacerbations (BTS/SIGN 2014); they should be initiated
promptly (Rowe 2001). It is thought that the intravenous or in-
tramuscular route offers no advantage over the oral route unless
compliance with treatment or intestinal absorption is a matter
of concern (Krishnan 2009; Lahn 2004). It is advised that oral
steroids be taken as a single dose after breakfast (BNF).
Current guidelines on dosing vary slightly between countries, and
often among different guideline producers within the same coun-
try. In the UK, the most recent (BTS/SIGN 2014) guidelines rec-
ommend for adults 40 to 50 mg daily oral prednisolone for at
least five days, or until recovery. The same guidelines recommend
a dose of 20 mg of prednisolone for children two to five years old,
and 30 to 40 mg for children older than five years. GINA 2015
recommendations are similar and suggest a dose of 1 mg/kg for
adult patients, up to a maximum daily dose of 50 mg, and 1 to 2
mg/kg for children aged six to 11 years, up to a maximum daily
dose of 40 mg. GINA 2015 guidance advises that a five- to seven-
day course in adults and three to five days in children is usually
adequate.
Currently evidence is insufficient to suggest that alternative
steroids, such as dexamethasone, offer any advantage over pred-
nisolone (BTS/SIGN 2014). Prednisolone is widely used interna-
tionally and is relatively inexpensive; a packet 28 × 5 mg tablets
costs just £1.29 in the UK (BNF). It is not necessary to taper
the dose when stopping, provided the patient is already using in-
haled corticosteroids, is not taking long-term oral steroids or has
required an acute course of over three weeks’ duration (BTS/SIGN
2014; GINA 2015).
How the intervention might work
Glucocorticoids, including prednisolone, are potent inhibitors of
inflammation and are used to treat a wide variety of inflammatory
and autoimmune conditions, including asthma (Barnes 2003; van
der Velden 1998). Glucocorticoids are thought to work by bind-
ing to a cellular glucocorticoid receptor, leading to down-regula-
tion of the expression of various genes involved in maintaining the
inflammatory process. This in turn leads to decreased inflamma-
tory cell recruitment and activation, up-regulation of beta2-recep-
tors, decreased microvascular permeability and decreased mucus
production (Barnes 1992). Research findings suggest more rapid
resolution of symptoms and reduced relapse rates among patients
treated with oral steroids (Alangari 2014; Krishnan 2009; Rowe
2007).
Why it is important to do this review
Despite their proven efficacy, use of steroids needs to be bal-
anced against their potential to cause important adverse events.
The problems associated with longer-term steroid therapy are
well established and include diabetes, osteoporosis, muscle wast-
ing, Cushing’s syndrome and linear growth restriction in children
(BNF). Indeed, regular use of even low to moderate daily doses of
inhaled corticosteroids is associatedwith amean reduction in linear
growth velocity of 0.48 cm/y among children (Zhang 2014).How-
ever, many important adverse events are associated with shorter-
term use, which is commonly recommended for asthma exacer-
bations. These side effects include insomnia, nausea, abdominal
distension, dyspepsia, malaise, vertigo, headache and (especially
in children) behavioural changes (BNF; Kayani 2002).
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Current evidence regarding optimal dosing of oral steroids for
asthma exacerbations is somewhat limited. Bowler 1992 ran-
domised 76 participants to receive low-, medium- or high-dose
intravenous hydrocortisone in an inpatient setting for 48 hours,
followed by low, medium or high doses of oral steroids give over
12 days. Study authors concluded that low-dose hydrocortisone
(50 mg, four times a day for 48 hours), followed by low-dose
prednisolone (20 mg daily, reduced to 5 mg over 12 days), was
as effective as higher doses. In a similar study of 20 participants
in the year 2000, researchers concluded that a one-week course of
oral steroids after a three-day course of intravenous steroids was
as effective as a two-week course (Hasegawa 2000). A study of 86
children aged two to 16 years concluded that an oral prednisolone
dose of 1mg/kg was equally effective as 2mg/kg but was associated
with fewer behavioural adverse events (Kayani 2002). Similarly,
Hewer 1998 identified no advantage of a 1 or 2 mg/kg dose over
a 0.5 mg/kg dose in a study of 98 children admitted to hospital
with acute asthma.
An overview or ’umbrella review’ of corticosteroid use in acute
asthma also addressed this question, suggesting that no evidence
shows that doses above 50 to 100 mg daily are beneficial, and
that a course duration of five to 10 days is sufficient for most dis-
charged patients (Krishnan 2009). Similar findings were reported
in Manser 2001. However, the conclusions presented in both of
these reviews are based on studies of hospitalised patients wherein
participants in at least one of the trial arms were receiving par-
enteral steroids.
O B J E C T I V E S
To assess the efficacy and safety of any dose or duration of oral
steroids versus any other dose or duration of oral steroids for adults
and children with an asthma exacerbation.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included parallel randomised controlled trials (RCTs), both
blinded and unblinded, that evaluated any dose or duration of
oral steroids versus any other dose or duration of oral steroids
for management of an asthma exacerbation. We excluded cross-
over trials because of the long-term effects of treatment with oral
steroids and the unpredictable timingof a second exacerbation.We
included studies reported as full text, those published as abstract
only and unpublished data.
Types of participants
We included studies of both adults and children with asthma,
diagnosed by clinician or according to national or international
guidelines, who were experiencing an exacerbation. We recorded
the severity of the exacerbation and the criteria used to define this.
We excluded studies that recruited participants with other respi-
ratory co-morbidities and those taking long-term oral steroids.
Types of interventions
We included studies comparing any dose or duration of oral
steroids with any other dose or duration of oral steroids. We in-
cluded studies that allowed any other co-interventions for man-
agement of an asthma exacerbation, such as inhaled or nebulised
short-acting beta2-agonists, provided they were not part of the
randomised treatment.
We included participants who had presented to a primary care-
based healthcare facility or emergency department and those who
had been admitted to hospital. We included participants who had
received intravenous or intramuscular steroid therapy before com-
mencing oral steroids, provided thiswas not part of the randomised
treatment and this route of administration had ceased before ran-
domisation to different oral dose or duration arms.
Eligable study comparisons included, but were not limited to, the
following examples.
1. Short versus long duration of the same dose, e.g. 40 mg oral
prednisolone daily for five days versus 40 mg oral prednisolone
daily for 10 days.
2. High versus low dose of the same duration, e.g. 20 mg oral
prednisolone daily for five days versus 40 mg oral prednisolone
daily for five days.
3. Short duration and high dose versus long duration and low
dose, e.g. 50 mg oral prednisolone for three days versus 20 mg
oral prednisolone daily for 10 days.
Types of outcome measures
Primary outcomes
1. Admission/re-admission to hospital.
2. Asthma symptoms at end of steroid course.
3. Serious adverse events.
Secondary outcomes
1. New exacerbation during post-treatment follow-up period.
2. Lung function tests at end of treatment/follow-up period
(trough forced expiratory volume in one second (FEV1)
preferred if available).
3. All adverse events/side effects.
Reporting by investigators of one or more of the outcomes listed
here was not an inclusion criterion for the review. Outcomes were
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chosen as those most important to patients after consultation with
a patient representative.
If more than one scale measuring the same construct was reported
within a study, or if different scales were used across studies, we
analysed them together using standardised mean differences, pro-
vided clinical heterogeneity was sufficiently low to make a pooled
analysis meaningful (e.g. we avoided combining different un-val-
idated symptom scales).
When possible, we extracted the types of adverse events experi-
enced; our user group research suggests that psychological/emo-
tional/behavioural side effects canbe particularly troublesomedur-
ing short-term steroid courses. This has been reported narratively
when meta-analysis was not possible.
Search methods for identification of studies
Electronic searches
We identified trials from the Cochrane Airways Group Specialised
Register (CAGR), which is maintained by the Information Spe-
cialist for the Group. The Register contains trial reports identified
through systematic searches of bibliographic databases including
the Cochrane Central Register of Controlled Trials (CENTRAL),
MEDLINE, EMBASE, the Cumulative Index to Nursing and Al-
lied Health Literature (CINAHL), the Allied and Complemen-
tary Medicine Database (AMED) and PsycINFO, and by hand-
searching of respiratory journals and meeting abstracts (please see
Appendix 1 for details). We searched all records in the CAGR us-
ing the search strategy presented in Appendix 2. We performed
the search in April 2016.
We conducted a search of
ClinicalTrials.gov (www.ClinicalTrials.gov) and theWorld Health
Organization (WHO) trials portal (www.who.int/ictrp/en/), also
in April 2016.
We searched all databases from their inception to the present, and
we imposed no restriction on language of publication.
Searching other resources
We checked the reference lists of all primary studies and review
articles for additional references. In a change to our protocol, we
did not search manufacturers’ websites, as the intervention med-
ication is made generically by a large number of manufacturers
worldwide.
We searched for errata or retractions from included studies pub-
lished in full text on PubMed (www.ncbi.nlm.nih.gov/pubmed)
in April 2016 and identified no errata or retractions.
Data collection and analysis
Selection of studies
Two review authors (RN and KMK or GM) independently
screened titles and abstracts for inclusion of all potential studies
identified as a result of the search and coded them as ’retrieve’
(eligible or potentially eligible/unclear) or ’do not retrieve’. We re-
trieved the full-text study reports/publications; two review authors
(RN and KMK or GM) independently screened full-text reports
and identified studies for inclusion, while identifying and record-
ing reasons for exclusion of ineligible studies. We resolved dis-
agreements through discussion; if required, we consulted the third
review author. We identified and excluded duplicates and collated
multiple reports of the same study, so that each study rather than
each report was the unit of interest in the review. We recorded the
selection process in sufficient detail to complete a PRISMA (Pre-
ferred Reporting Items for Systematic Reviews and Meta-Anal-
yses) flow diagram and Characteristics of excluded studies table
(Moher 2009).
Data extraction and management
Weused a data collection form that hadbeenpiloted on at least two
studies in the review to record study characteristics and outcome
data. In a change from the protocol, one review author (RN)
extracted study characteristics from included studies and another
review author (KMK) independently spot-checked the extracted
information for accuracy.We extracted the following information.
1. Methods: study design, total duration of study, details of
any ’run-in’ period, number of study centres and locations, study
setting, withdrawals and date of study.
2. Participants: N, mean age, age range, gender, severity of
condition, diagnostic criteria, baseline lung function, smoking
history, inclusion criteria and exclusion criteria.
3. Interventions: intervention, comparison, concomitant
medications and excluded medications.
4. Outcomes: primary and secondary outcomes specified and
collected and time points reported.
5. Notes: funding for trial and notable conflicts of interest of
all trial authors.
Two review authors (RN and KMK or GM) independently ex-
tracted outcome data from included studies. We noted in the
Characteristics of included studies table if outcome data were not
reported in a useable way. We resolved disagreements by reaching
consensus or by involving the third person (RN, KMK or GM).
One review author (RN or KMK) transferred data into the Review
Manager file (RevMan 2014). We double-checked that data were
entered correctly by comparing data presented in the systematic
review with data provided in the study reports. We ensured that
KMKwas not involved in both transferring data into RevMan and
spot-checking for accuracy.
Assessment of risk of bias in included studies
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Two review authors (RN and KMK or GM) independently as-
sessed risk of bias for each study using the criteria outlined in the
CochraneHandbook for Systematic Reviews of Interventions (Higgins
2011). We resolved disagreements by discussing them or by in-
volving another review author (RN, KMK or GM). We assessed
risk of bias according to the following domains.
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias.
We graded each potential source of bias as high, low or unclear and
provided a quote from the study report together with a justification
for our judgement in the ’Risk of bias’ table. We summarised
risk of bias judgements across different studies for each of the
domains listed.We considered blinding separately for different key
outcomes when necessary (e.g. for unblinded outcome assessment,
risk of bias for all-cause mortality may be very different than for
a patient-reported pain scale). When information on risk of bias
was related to unpublished data or correspondence with a trialist,
we noted this in the ’Risk of bias’ table.
When considering treatment effects, we took into account the risk
of bias for studies that contributed to that outcome.
Assesment of bias in conducting the systematic
review
We conducted the review according to the published protocol
and reported any deviations from it in the Differences between
protocol and review section of the systematic review.
Measures of treatment effect
We analysed dichotomous data as odds ratios or (for very rare
events) as risk differences, which takes into account the zero cells
in an analysis. We analysed continuous data as mean differences
or standardised mean differences. We entered data presented as
a scale with a consistent direction of effect. We extracted change
from baseline scores in preference to endpoint scores, if both were
reported.
We undertook meta-analyses only when this was meaningful (i.e.
when treatments, participants and the underlying clinical question
were similar enough for pooling to make sense).
We narratively described skewed data reported as medians and
interquartile ranges.
Whenmultiple trial armswere reported in a single trial, we planned
to include only the relevant arms. However, no included study
reported a treatment arm irrelevant to this review. If two compar-
isons (e.g. drug A vs placebo and drug B vs placebo) are combined
in the samemeta-analysis, we will halve the control group to avoid
double-counting.
We dealt with children (i.e. average age of participants younger
than 16) and adults separately in the review.
For our analyses, we attempted to group data into ’high-dose’
courses (e.g. > 50 mg daily dose in adults or > 2 mg/kg in chil-
dren, i.e. higher than current recommendations) versus ’low-dose’
courses (i.e. within current recommendations), and ’longer dura-
tion’ courses (e.g. > 7 days, again longer than most recommenda-
tions) versus ’short duration’ courses.
Further grouping, determined by comparisons made within the
studies, will be described later in the review.
Unit of analysis issues
The unit of analysis was the patient (i.e. number of participants
admitted tohospital at least once rather thannumber of admissions
per participant).
Dealing with missing data
We contacted investigators or study sponsors to verify key study
characteristics and to obtain missing numerical outcome data
when possible (e.g. when a study was identified as abstract only).
When this was not possible, and missing data were thought to
introduce serious bias, we explored the impact of including such
studies in the overall assessment of results by conducting a sensi-
tivity analysis.
Assessment of heterogeneity
We used the I² statistic to measure heterogeneity among the trials
in each analysis. If we identified substantial heterogeneity, we re-
ported this. We were not able to carry out any of our pre-specified
subgroup analyses because combinable data were lacking.
Assessment of reporting biases
We were unable to pool more than 10 trials, and so we could not
create a funnel plot to explore possible small study and publication
biases.
Data synthesis
We used a random-effects model and performed a sensitivity anal-
ysis with a fixed-effect model.
Summary of findings table
We created a ’Summary of findings’ table using the following out-
comes.
1. Admission/re-admission to hospital.
2. Asthma symptoms at end of steroid course.
3. Serious adverse events.
4. New exacerbation in post-treatment follow-up period.
5. All adverse events/side effects.
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6. Lung function tests at end of treatment/follow-up period.
We used the five GRADE (Grades of Recommendation, Assess-
ment, Development and Evaluation Working Group) considera-
tions (study limitations, consistency of effect, imprecision, indi-
rectness and publication bias) to assess the quality of a body of
evidence as it related to the studies that contributed data to the
meta-analyses for pre-specified outcomes. We used methods and
recommendations described in Section 8.5 and Chapter 12 of the
CochraneHandbook for Systematic Reviews of Interventions (Higgins
2011), while using GRADEpro software (GRADEproGDT). We
justified all decisions to downgrade or upgrade the quality of stud-
ies by using footnotes, and we made comments to aid the reader’s
understanding of the review when necessary.
Subgroup analysis and investigation of heterogeneity
We planned to carry out the following subgroup analyses if we
found significant heterogeneity.However, we anticipated correctly
that we would identify few studies contributing data to each out-
come within the possible comparisons outlined under Types of
interventions. Therefore, we did not attempt to perform these
subgroup analyses and instead presented information on these po-
tential effect modifiers in Table 1.
1. Severity of asthma exacerbation according to mean baseline
characteristics (e.g. mild vs moderate vs severe).
2. Hospitalised participants versus non-hospitalised
participants.
3. Treatment with intramuscular or intravenous steroids
before randomisation versus no treatment with intramuscular or
intravenous steroids before randomisation.
4. Asthma severity according to reported background
characteristics (e.g. Global Initiative for Asthma (GINA) 1 and 2
vs GINA 3 and 4).
We planned to use the following outcomes in subgroup analyses.
1. Admission/re-admission to hospital.
2. Asthma symptoms at end of treatment course.
3. Serious adverse events.
4. All adverse events.
We planned to use the formal test for subgroup interactions in
Review Manager 5 (RevMan 2014), had subgroup analysis been
possible.
We included all adverse events as an outcome in the subgroup
analysis, as user group feedback suggests that many of the adverse
events experienced would not be classified as ’serious’ according
to standard definitions in research, but can nonetheless have a
substantial impact on daily functioning.
Sensitivity analysis
We planned to carry out the following sensitivity analyses.
1. Studies at high risk of selection bias.
2. Unpublished data (i.e. no peer-reviewed full paper
available).
R E S U L T S
Description of studies
Full details of the conduct and characteristics of each included
study can be found in the Characteristics of included studies ta-
bles and reasons for exclusion when full texts had to be viewed are
given in the Characteristics of excluded studies table.
Results of the search
We identified 1297 references through electronic database searches
and an additional 109 records through searches of clinicaltrials.gov
and the World Health Organization (WHO) trials portal (http://
apps.who.int/trialsearch/). We excluded most (n = 1335) of these
references on the basis of title and abstract. We retrieved 71 full
texts for more detailed assessment and at this stage excluded 47
additional references (related to 39 individual studies). Reasons
for exclusion included wrong comparator, wrong intervention and
not a randomised controlled trial. We also excluded three studies
that were ongoing, and one study (reported as an abstract only) is
still awaiting classification, despite attempts to contact the study
author to confirmwhether itmet out inclusion criteria.We present
trial flow in Figure 1.
11Different oral corticosteroid regimens for acute asthma (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 1. Study flow diagram.
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Included studies
Eighteen studies met our inclusion criteria, 16 of which con-
tributed data to at least one meta-analysis. These studies included
a total of 2438 participants who were randomly assigned to com-
parisons of interest in this review. The largest study included 628
participants, and the smallest just 15. The mean total number of
participants was 135, and themedian 93. Investigators reported 14
trials as full peer-reviewed articles, three as abstracts only (Aboeed
2014; Ghafouri 2010; Viska 2008) and one on the clinicaltri-
als.gov website (NCT00257933), for which we obtained addi-
tional unpublished data directly from the trial contact person. We
present a summary of the characteristics of included studies in
Table 1.
Methods
As per our protocol, all included trials were RCTs with parallel
design that compared one dose or duration of oral steroids ver-
sus another dose or duration. One study included three relevant
arms: high-, medium- and low-dose oral prednisolone. Trial du-
ration varied, with oral steroid treatment courses ranging from
just a single dose to seven weeks of treatment. All studies in-
cluded a post-treatment follow-up period, which ranged in dura-
tion from seven days to six months. No studies reported a run-in
period, as recruitment was triggered by an unscheduled presenta-
tion with an acute exacerbation of asthma. Outcomes data were
extracted at the end of steroid treatment or at the last time point
reported, or at both times if available. Trials were conducted in a
variety of countries worldwide, but most were carried out in the
USA (Aboeed 2014; Cydulka 1998; Ghafouri 2010; Greenberg
2008; Kayani 2002; Kravitz 2011; Lederle 1987; NCT00257933;
Qureshi 2001) and the UK (Jones 2002; Langton Hewer 1998;
O’Driscoll 1993). The remainder were carried out in Australia
(Chang 2008), Canada (Altamimi 2006), Japan (Hasegawa 2000),
Indonesia (Viska 2008), India (Karan 2002) and Ireland (Cronin
2015).
Participants
We included studies involving both children and adults. Nine
studies (Altamimi 2006; Chang 2008; Cronin 2015; Ghafouri
2010; Greenberg 2008; Kayani 2002; Langton Hewer 1998;
NCT00257933; Qureshi 2001) recruited only children (age range
one to 18 years depending on the individual study), and seven
studies (Cydulka 1998; Jones 2002; Karan 2002; Kravitz 2011;
Lederle 1987; O’Driscoll 1993; Viska 2008) recruited only adults
(age range 16 to 78 years depending on the individual study).
Two studies (Aboeed 2014; Hasegawa 2000) did not report the
age range of participants, but the steroid doses administered in
Aboeed 2014 would be consistent with adult participants. Most
studies did not specify the ethnicity of participants.
All studies included participants with acute exacerbations of
asthma. Although reported as having asthma, most of the partici-
pants in Lederle 1987 were older men who were current smokers
or ex-smokers, and many may in fact have had chronic obstruc-
tive pulmonary disease (COPD) with a degree of reversibility. In
most cases, researchers did not report baseline asthma severity and
severity of the asthma attack. However, in the majority of stud-
ies (Aboeed 2014; Altamimi 2006; Chang 2008; Cronin 2015;
Cydulka 1998; Ghafouri 2010; Greenberg 2008; Karan 2002;
Kayani 2002; Kravitz 2011; Qureshi 2001), researchers recruited
participants in the emergency department (ED) or at an outpatient
clinic, and the inclusion criteria in most of these studies required
that they must be well enough to be discharged home. Four stud-
ies (Jones 2002; Langton Hewer 1998; Lederle 1987; O’Driscoll
1993) recruited participants and commenced randomised treat-
ment on an inpatient basis but completed treatment at home. In
one study (NCT00257933), randomised steroid treatment was
continued for 48 hours or until discharge, whichever came sooner,
followed by five to 10 days of standard oral steroid treatment at the
discretion of the treating physician. One study did not report the
specific setting in which treatment was commenced (Viska 2008),
and in Hasegawa 2000, treatment was initiated in hospital, but
it is not clear whether participants remained as inpatients for the
duration of their steroid treatment.
Interventions
Studies included a variety of comparisons: longer versus shorter
course of prednisolone (Chang 2008; Hasegawa 2000; Jones
2002); higher versus lower dose of prednisolone (Kayani 2002;
Langton Hewer 1998; NCT00257933; Viska 2008); longer
course of prednisolone versus shorter course of dexametha-
sone (Aboeed 2014; Altamimi 2006; Cronin 2015; Greenberg
2008; Kravitz 2011; Qureshi 2001); tapering versus non-tapering
course of prednisolone (Cydulka 1998; Karan 2002; O’Driscoll
1993); long-tapering versus short-tapering course of prednisolone
(Lederle 1987); and finally long versus short course of dexametha-
sone (Ghafouri 2010). Dosing also varied across studies; we have
extracted this information and presented it in the Characteristics
of included studies tables, along with the ’prednisolone-equiva-
lent’ total dose received. All participants in Hasegawa 2000 re-
ceived three days of intravenous methylprednisolone before com-
mencing randomised oral steroid treatment.
Although we did not set out to compare different types of oral
steroids, we included the dexamethasone versus prednisolone com-
parison because these agents were given over different durations,
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and this was part of our scope. We meta-analysed these trials sep-
arately because, unlike studies that compared a different dose or
duration of the same drug,most of these studies gave almost equiv-
alent total doses of steroid in each intervention arm, so any be-
tween-group differences may be related to drug-specific factors in-
cluding adherence or palatability. We recognise that in a clinical
setting, drug-specific factors, such as convenience for the patient,
may affect an individual practitioner’s choice of drug or regimen.
Most studies stated that participants were allowed to continue use
of specified rescue and preventer medication for asthma through-
out the study, and in some trials, frequency of use of rescue med-
ication, such as a short-acting beta2-agonist, was an efficacy out-
come.
Outcomes
Outcomes reported were not consistent across reviews, and vali-
dated scales were not always used. Most studies (n = 13) reported
some measure of asthma symptoms, at the end of treatment or
follow-up, or time taken for resolution of symptoms. Most (n =
13) also reported relapse rates, defined usually as an unscheduled
visit to the ED or another healthcare provider during the follow-
up period. Three studies specifically reported hospitalisation dur-
ing the follow-up period, and seven studies reported new exacer-
bations or another course of oral steroids prescribed during the
follow-up period. Various measures of lung function were also
frequently reported (n = 10), as was compliance with prescribed
steroid therapy (n = 6). Adverse events were explicitly stated as an
outcome measure in only six studies. Four studies recorded res-
cue medication use, four reported vital signs and three reported
asthma severity scores. Two studies assessed adrenal suppression.
One study reported Paediatric Asthma Caregiver’s Quality of Life
Questionnaire (PACQLQ), two reported school days or workdays
missed and another used the asthma control test.
Excluded studies
We excluded 46 references (related to 38 individual studies) after
assessment of full-text articles. We excluded 13 studies, as they
used a comparator not of interest in this review, for example, in-
travenous or inhaled steroids were compared with oral steroids.
We excluded 12 studies because the intervention was not of inter-
est in this review, for example, studies comparing different doses
of intravenous steroids in the acute setting, or interventions in-
cluding additional randomised treatments not of interest in this
review. We excluded six studies as they were not randomised con-
trolled trials and another two because they used a cross-over trial
design. One study was in fact a review article, and another study
recruited a mixed population of patients with COPD and asthma.
We excluded two studies that were ongoing (NCT01241006;
NCT02192827), and one study (Tanifuji 2001; reported as an
abstract only) is still awaiting classification, despite attempts to
contact the study author to confirm whether it met out inclusion
criteria.
Risk of bias in included studies
For details of the risk of bias rating for each study and the support-
ing evidence for each rating, see the Characteristics of included
studies table. A summary of risk of bias judgements by study and
domain (sequence generation, allocation concealment, blinding,
incomplete data and selective reporting) can be found in Figure 2.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Six studies (Altamimi 2006; Chang 2008; Cronin 2015; Jones
2002; Langton Hewer 1998; O’Driscoll 1993) described the gen-
eration of a random sequence and concealment of allocation of
participants in sufficient detail for review authors to assess them
as having low risk of selection bias. We considered five other stud-
ies (Cydulka 1998; Greenberg 2008; Kayani 2002; Kravitz 2011;
NCT00257933) to be at low risk of bias for random sequence
generation but at unclear risk of bias for allocation concealment,
which was not described in sufficient detail to allow a judgement.
Six studies (Aboeed 2014; Ghafouri 2010; Hasegawa 2000; Karan
2002; Lederle 1987; Viska 2008) did not provide sufficient de-
tails of random sequence generation or allocation concealment for
review authors to make a judgement, and so we considered these
studies to be at unclear risk of bias in both domains. We assessed
Qureshi 2001 as having high risk of bias for random sequence
generation and allocation concealment, as participants were allo-
cated to the two intervention arms on the basis of the day of the
month they presented to the ED.
Blinding
We judged most studies (n = 11; Altamimi 2006; Chang 2008;
Cydulka 1998;Greenberg 2008; Jones 2002;Kayani 2002;Kravitz
2011; Langton Hewer 1998; Lederle 1987; NCT00257933;
O’Driscoll 1993) to be at low risk of performance bias, as par-
ticipants and trial personnel were adequately blinded. Five stud-
ies (Altamimi 2006; Chang 2008; Langton Hewer 1998; Lederle
1987; NCT00257933) clearly described blinding of outcome as-
sessors, and we judged these studies to be at low risk of detection
bias. We assessed the remaining six studies as having unclear risk
of detection bias, as blinding of outcome assessors was not clearly
described.
We considered Aboeed 2014 to be at unclear risk of bias for both
performance and detection bias, as the abstract did not contain
enough detail to allow a judgement. Four studies (Ghafouri 2010;
Hasegawa 2000; Karan 2002; Viska 2008) were open-label and
were considered to be at high risk of performance and detection
bias. In Cronin 2015, also an open-label study, outcome asses-
sors for the primary outcome (paediatric respiratory assessment
measure (PRAM)) at day 4 were unaware of group allocation, but
other participant-reported or influenced outcomes (e.g. decision
to re-present to a healthcare practitioner) may have been affected
by knowledge of group allocation, so we rated this study as having
unclear risk of detection bias and high risk of performance bias.
We considered one study (Qureshi 2001) to be at high risk of
performance bias, as the trial was unblinded, but the primary out-
come - decision to seek medical care for deteriorating symptoms -
was assessed independently of study investigators, and so we rated
the risk of detection bias as unclear.
Incomplete outcome data
We assessed 12 studies (Altamimi 2006; Chang 2008; Cronin
2015; Cydulka 1998; Hasegawa 2000; Jones 2002; Karan 2002;
Kayani 2002; Lederle 1987; NCT00257933; O’Driscoll 1993;
Qureshi 2001) to be at low risk of attrition bias, as they had low
and balanced withdrawal, and all participants who withdrew were
clearly accounted for in the trial flow. We assessed Aboeed 2014
and Viska 2008, both conference abstracts, as having unclear risk,
as they did not describe the number randomised to, or withdrawn
from, each treatment arm.
We assessed Langton Hewer 1998 to be at high risk; attrition in
the intervention groups was unbalanced (< 10% in the medium-
and low-dose groups and 20% in the higher-dose group), and
although all withdrawals were accounted for in the text of the
report, this imbalance may have affected the findings. We assessed
Ghafouri 2010, a conference abstract, to be at high risk of attrition
bias because of unbalanced attrition in intervention groups, and
because the reasons for withdrawal were not stated. We assessed
Greenberg 2008 also to be at high risk, as approximately half of
the participants randomised to each treatment did not complete
the trial, and although baseline details are given for those who
completed and those who did not, how this high level of attrition
may have affected the findings is unclear. Finally, we assessed
Kravitz 2011 as having high risk of attrition bias, as 30% (85 out
of 285) of all randomised participants did not complete the trial
as the result of admission to hospital after they were randomised
or loss to follow-up, and their outcomes remain unknown.
Selective reporting
We assessed 13 studies (Altamimi 2006; Chang 2008; Cronin
2015; Cydulka 1998; Ghafouri 2010; Greenberg 2008; Hasegawa
2000; Jones 2002; Karan 2002; Kayani 2002; Kravitz 2011;
Langton Hewer 1998; Qureshi 2001) to be at low risk of reporting
bias, although we were able to find prospectively registered proto-
cols only for Chang 2008, Cronin 2015 and Ghafouri 2010.
We assessed Aboeed 2014 and Viska 2008, both conference ab-
stracts, to be at high risk, as they provided minimal details and
could not be included in the quantitative synthesis. We assessed
NCT00257933 to be at unclear risk, as the trial has not yet been
published. Some results are posted on clinicaltrials.gov, and the
study authors kindly provided uswith an unpublishedmanuscript,
but some listed outcomes are as yet not fully reported (peak flow,
clinical asthma score).
We considered Lederle 1987 to be at high risk, as not all outcomes
were reported in a way that allowedmeta-analysis, including FEV1
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(reported as percentage of baseline value without variance) and
diary outcomes (reported narratively in the text with minimal
supportingnumerical data). Similarly, we assessedO’Driscoll 1993
to be at high risk, as many of the diary outcomes were not reported
numerically, and data were displayed graphically with no variance.
Other potential sources of bias
Most studies did not report their funding source, and for those
that did, this was not considered to be a likely source of bias. We
assessed Cronin 2015 as being at unclear risk of other bias, as
investigators allowed participants to enrol more than once in the
trial. This may have led to the same participant contributing to
outcomes twice; how the trial authors adjusted the analyses to take
this into account is not clear, as they simply state that a “descriptive
analysis of the patients enrolled multiple times was performed”.
Effects of interventions
See: Summary of findings for the main comparison Adults:
higher dose/longer course compared with lower dose/shorter
course for acute asthma; Summary of findings 2 Adults:
prednisolone compared with dexamethasone for acute asthma;
Summary of findings 3 Children: higher dose/longer course
compared with lower dose/shorter course for acute asthma;
Summary of findings 4 Children: prednisolone compared with
dexamethasone for acute asthma
Structure of the analysis
Wechose to analyse trials in adults and trials in children completely
separately in this review.
Structure of the meta-analysis
We created four main comparison headings within the analysis
tree. For each comparison, we chose to meta-analyse results only
when the interventions and outcomes measured were sufficiently
similar for pooling to make sense.
Adults: higher dose/longer course versus lower dose/shorter
course
This comparison included all studies in adults that compared a
higher dose or a longer course with a lower dose or a shorter course
of the same oral steroid (Cydulka 1998; Hasegawa 2000; Jones
2002; Karan 2002; Lederle 1987; O’Driscoll 1993; Viska 2008),
for example, 40 mg of prednisolone once daily for 10 versus five
days, or 36 mg versus 12 mg of prednisolone daily for two weeks.
Adults: prednisolone versus dexamethasone
This comparison included all studies in adults that comparedpred-
nisolone with dexamethasone (Aboeed 2014; Kravitz 2011), for
example, 40 mg prednisolone daily for five days versus 16 mg of
dexamethasone daily for two days.
Children: higher dose/longer course versus lower
dose/shorter course
This comparison included all studies in children that compared a
higher dose or a longer course with a lower dose of a shorter course
of the same oral steroid (Chang 2008; Ghafouri 2010; Kayani
2002; Langton Hewer 1998; NCT00257933), for example, 1 mg/
kg daily prednisolone for five versus three days, or 2 mg/kg daily
versus 1 mg/kg daily prednisolone for five days.
Children: prednisolone versus dexamethasone
This comparison included all studies in children that compared
prednisolone with dexamethasone (Altamimi 2006; Cronin 2015;
Greenberg 2008; Qureshi 2001), for example, 1 mg/kg pred-
nisolone twice daily for five days versus dexamethasone 0.6 mg/
kg once daily for one day.
Structure of the narrative synthesis
Below, we present the results narratively according to our pre-spec-
ified outcomes. We begin with the primary outcomes: admission/
re-admission to hospital; asthma symptoms; and serious adverse
events. Within each outcome, we describe effects of the interven-
tions in adults, followed by effects in children, clearly specifying
which of the above comparisons yielded the extracted data. We
then describe the secondary outcomes: new exacerbation in the
follow-up period; lung function tests; and all adverse events/side
effects, according to the same pattern.
Primary outcomes
Admission/re-admission to hospital
Overall, our results demonstrated no difference in admission or
re-admission to hospital between participants prescribed a longer
course or a higher dose of oral steroids and those prescribed a
shorter course or a lower dose, or between those prescribed pred-
nisolone and those prescribed dexamethasone. The requirement
for admission at initial presentation was an exclusion criterion for
many of the included studies. In those reporting admissions or
re-admissions, events were generally rare, and differences between
interventions and populations in the included studies precluded
meaningfulmeta-analysis, resulting in imprecise estimates and low
confidence in the result.
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Admission at initial presentation: children
Four studies in children (Altamimi 2006; Cronin 2015; Ghafouri
2010; Qureshi 2001) reported admission at initial presentation.
Altamimi 2006, Cronin 2015 and Qureshi 2001 - studies com-
paring prednisolone and dexamethasone - did not detect a differ-
ence in admission rates between intervention groups (Analysis 4.1;
odds ratio (OR) 1.08, 95% confidence interval (CI) 0.74 to 1.58;
participants = 1007; I2 = 0%), but the confidence intervals include
an important reduction and increase in admissions. In addition,
one of the studies contributing to this analysis (Qureshi 2001) was
considered to be at high risk of selection bias, and another study
(Cronin 2015) was open-label and therefore was at high risk of
performance and detection bias for this outcome. We therefore
have low confidence in the finding. Ghafouri 2010, a study com-
paring a longer course versus a shorter course of the same dose
of dexamethasone, also reported no difference in admissions at
initial presentation (Analysis 3.1; OR 1.66, 95% CI 0.60 to 4.61;
participants = 125) but again with wide confidence intervals. It
is important to note that admission at initial presentation would
have been measured before the differing durations of treatment
would have had an impact, and so this result is of limited value.
Re-admission during follow-up period: adults
Re-admission to hospital during the follow-up periodwas reported
by five studies of adult participants (Hasegawa 2000; Jones 2002;
Kravitz 2011; Lederle 1987; O’Driscoll 1993).
In four studies that compared a longer course versus a shorter
course of prednisolone (Hasegawa 2000; Jones 2002; Lederle
1987; O’Driscoll 1993), no difference in re-admissions was found
between intervention groups, but events were rare and confidence
intervals include the possibility of harm and the possibility of
benefit from a longer or a shorter course (Analysis 1.1; OR 1.35,
95% CI 0.38 to 4.79; participants = 142; studies = 4; I2 = 0%). Of
note, the study carrying the greatest weight in this analysis (Lederle
1987) likely recruited participants with co-morbid COPD, so this
outcomewas additionally downgraded for indirectness of the study
population. Similarly, the study comparing prednisolone versus
dexamethasone in adults (Kravitz 2011) reported infrequent re-
admissions to hospital and consequently an imprecise result, and
was considered to be at high risk of attrition bias (Analysis 2.1;
OR 0.35, 95% CI 0.04 to 3.47; participants = 200).
Re-admission during follow-up period: children
Re-admission to hospital during the follow-up period was re-
ported by eight studies in children (Altamimi 2006; Chang 2008;
Cronin 2015;Ghafouri 2010;Kayani 2002; LangtonHewer 1998;
NCT00257933; Qureshi 2001).
Three studies in children compared a higher dose versus a
lower dose of prednisolone (Kayani 2002; Langton Hewer 1998;
NCT00257933), one compared a longer course versus a shorter
course of prednisolone (Chang 2008) and one compared a longer
course versus a shorter course of dexamethasone (Ghafouri 2010).
Again, events were rare, with only nine participants requiring re-
admission across all five studies (with two studies reporting no
events), resulting in wide confidence intervals in each of the three
studies reporting events (Analysis 3.2). As the interventions were
not sufficiently similar, we did not perform a meta-analysis and
our confidence in these estimates is low or very low.
Altamimi 2006, Cronin 2015 and Qureshi 2001 compared pred-
nisolone versus dexamethasone, and although all three studies re-
ported re-admissions, they were infrequent, resulting in wide con-
fidence intervals (Analysis 4.2; OR 0.44, 95% CI 0.15 to 1.33;
participants = 985; I2 = 0%), and our confidence in the finding was
further reduced by the risk of selection bias identified in Qureshi
2001 and by lack of blinding in Cronin 2015.
Asthma symptoms
Asthma symptoms were reported by several included studies, but
investigators used a variety of measures and time points, limiting
meaningful meta-analysis. In general, individual studies did not
detect an important difference between intervention arms but with
a high level of imprecision.
Adults
In adults, asthma severity score was reported by Jones 2002 (mean
of individuals’ mean overall severity 1 to 7; 1 = no symptoms, 7
= worst symptoms) on days six to 21; Analysis 1.2). The result
showed modest benefit with a longer course of prednisolone over
a shorter course, but the clinical importance of this is not clear
(mean difference (MD) -0.70, 95%CI -1.28 to -0.12; participants
= 44), and our confidence in this estimate is low. O’Driscoll 1993,
a small study comparing a tapered (longer) course of prednisolone
versus a non-tapered (shorter) course, reported the number of par-
ticipants with complete resolution of asthma symptoms by day
28 but provided insufficient data to allow conclusions (Analysis
1.3; OR 0.55, 95% CI 0.13 to 2.26; participants = 35), and again
we have low confidence in this estimate. Kravitz 2011, a trial that
compared prednisolone versus dexamethasone, reported the num-
ber of participants who had resumed normal activities within three
days. Results suggest amodest benefit of dexamethasone over pred-
nisolone (Analysis 2.2; OR 0.44, 95% CI 0.19 to 1.01; partici-
pants = 191), but the confidence intervals do not fully exclude no
differences, and the one study contributing to this outcome was
assessed to be at high risk of attrition bias.
Children
In children, clinical asthma score at discharge was reported by
Langton Hewer 1998, a study that compared high-, medium- and
low-dose prednisolone. These findings are inconsistent, have un-
certain clinical importance and show no clear benefit of a higher
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or a lower dose (Analysis 3.3). Chang 2008, a trial of a five- versus
three-day course of prednisolone, reported the number of children
symptom free at seven days and did not detect a difference be-
tween intervention groups (Analysis 3.4; OR 1.22, 95% CI 0.67
to 2.19; participants = 201). We downgraded this outcome once
for imprecision, but we are otherwise moderately confident in
this estimate. Altamimi 2006, Cronin 2015 and Qureshi 2001 -
all trials of prednisolone versus dexamethasone - reported asthma
symptoms using different scales. Altamimi 2006 reported both
the pulmonary index score (PIS) at day five and the mean num-
ber of days for the patient self assessment sheet (PSAS) score to
return to normal. Researchers detected no between-group differ-
ences (Analysis 4.3;MD -0.10, 95%CI -0.45 to 0.25; participants
= 110; Analysis 4.4; MD 0.01, 95% CI -0.67 to 0.69; participants
= 110), but we have low confidence in both estimates as the result
of imprecision and lack of clarity about the rigorous validation
of the scoring systems used. Cronin 2015 reported the paediatric
respiratory assessment measure (PRAM) score at day four as the
primary outcome for which the study was powered and detected
no between-group differences (Analysis 4.5; MD 0.00, 95% CI
-0.36 to 0.36). Qureshi 2001, again a trial of prednisolone ver-
sus dexamethasone, reported separately persistent cough, wheeze,
chest tightness, night wakening and difficulty maintaining normal
activities (Analysis 4.6). This study detected no between-group
differences, but we assessed this trial as having high risk of selec-
tion and performance bias.
Serious adverse events
Included studies infrequently reported serious adverse events, and
none of the studies in adults specifically reported this outcome.
Five studies in children (Altamimi 2006; Chang 2008; Langton
Hewer 1998; NCT00257933; Qureshi 2001), including a total
of 695 participants, reported that there were no serious adverse
events.
Secondary outcomes
New exacerbations during the follow-up period
New exacerbations during the follow-up period were reported by
seven studies in adults (Cydulka 1998; Hasegawa 2000; Jones
2002; Karan 2002; Kravitz 2011; Lederle 1987; O’Driscoll 1993)
and eight studies in children (Altamimi 2006; Chang 2008;
Cronin 2015; Ghafouri 2010; Greenberg 2008; Kayani 2002;
NCT00257933; Qureshi 2001). New exacerbations were classi-
fied in two main ways: those requiring an unscheduled visit to a
healthcare provider, and those requiring the prescription of addi-
tional oral corticosteroids. Overall, no included study reported a
clear, unbiased benefit of one regimen over another, and varied
interventions and definitions of an exacerbation prevented a uni-
fying meta-analysis.
Exacerbation requiring a visit to a healthcare provider: adults
Four small studies in adults (Cydulka 1998; Hasegawa 2000;
Karan 2002;O’Driscoll 1993; total n = 96; Analysis 1.4) that com-
pared longer versus shorter courses of prednisolone or stable versus
tapered prednisolone reported exacerbations requiring a visit to a
healthcare professional during the follow-up period. Only eight
events were reported across the four studies, resulting in insuffi-
cient data to ascertain possible differences between interventions
for this outcome. Our confidence in these estimates was further
reduced by concerns about selection, performance and detection
bias in two of the contributing studies (Hasegawa 2000; Karan
2002) and by indirectness of the treatment regimens used, which
deviated widely from current standard practice.
Kravitz 2011, a study involving adults that compared prednisolone
versus dexamethasone, separately reported exacerbations requiring
an emergency department visit and those requiring a visit to a
primary healthcare provider. Investigators detected no differences
between the two interventions for this outcome, but confidence
intervals did not exclude the possibility of risk or harm for either
intervention (Analysis 2.3; Analysis 2.4); we assessed this study to
be at high risk of attrition bias, further limiting our confidence in
this estimate.
Exacerbation requiring a visit to a healthcare provider:
children
Five studies in children - one comparing a longer versus a shorter
course of dexamethasone (Ghafouri 2010; Analysis 3.7) and four
comparing prednisolone versus dexamethasone (Altamimi 2006;
Cronin 2015; Greenberg 2008; Qureshi 2001; Analysis 4.8) re-
ported exacerbations requiring an unscheduled visit to a health-
care provider during the follow-up period. The results reported
by Ghafouri 2010 favoured a shorter over a longer course of dex-
amethasone for this outcome but with wide confidence intervals,
which do not exclude the possibility that the longer course may
be more beneficial (OR 2.17, 95% CI 0.67 to 7.01; participants
= 100). In addition to our serious concerns about imprecision, we
considered this study to be at high risk of bias in several domains.
The four studies investigating prednisolone versus dexamethasone
favoured prednisolone, but again the confidence intervals did not
exclude potential risk or benefit of either steroid for this outcome
(Analysis 4.8; OR 0.85, 95% CI 0.54 to 1.34; participants = 981;
I2 = 0%). Of note, Qureshi 2001 carried out an intention-to-
treat analysis for this outcome, assuming that all children excluded
because of vomiting or lost to follow-up had a relapse; this analysis
favoured dexamethasone, but confidence intervals did not exclude
the possibility of no differences (OR 0.61, 95% CI 0.35 to 1.05),
and we assessed this study as having high risk of selection and
performance bias. We also rated Cronin 2015 as having high risk
of performance and detection bias for this outcome, and we are
uncertain about the effect that repeated enrolment of the same
participants may have had on this outcome.
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Exacerbation requiring additional oral corticosteroids: adults
Three studies in adults (Jones 2002; Lederle 1987; O’Driscoll
1993) that compared longer courses versus shorter courses of pred-
nisolone reported exacerbations requiring an additional course of
oral steroids during the follow-up period. Results favoured a longer
course of steroids, but the confidence intervals did not exclude
the possibility of no differences or benefit derived from a shorter
course (Analysis 1.5; OR 0.62, 95% CI 0.23 to 1.68; participants
= 122; I2 = 0%). In addition, as already described, our confidence
in the applicability of this finding to a population with asthma is
reduced by the likelihood that many of the participants in Lederle
1987 had co-morbid COPD, and that the higher event rate in this
study dominated the analysis.
Viska 2008, a conference abstract, also reported ’relapse’. We did
not include this study in the quantitative synthesis, as the total ’n’
for each intervention group (higher- vs lower-dose prednisolone)
was not given. However, the abstract reported no differences be-
tween the two treatment arms for this outcome.
Exacerbation requiring additional oral corticosteroids:
children
Finally, five studies in children - two comparinghigher versus lower
doses of prednisolone (Kayani 2002; NCT00257933), one com-
paring a longer versus a shorter course of prednisolone (Chang
2008), one comparing a longer versus a shorter course of dex-
amethasone (Ghafouri 2010) and one comparing prednisolone
and dexamethasone (Cronin 2015) - reported exacerbations re-
quiring an additional course of oral steroids. As for previous out-
comes, events in Chang 2008, Ghafouri 2010, Kayani 2002 and
NCT00257933 were rare, and none of these analyses demon-
strated a conclusive benefit of one regimen over the other (Analysis
3.6). Our confidence in these estimates is moderate (Chang 2008)
or low (Ghafouri 2010; Kayani 2002; NCT00257933) because
of concerns about imprecision and risk of bias. Cronin 2015 de-
tected benefit in favour of prednisolone (Analysis 4.9; OR 0.29,
95% CI 0.10 to 0.81; participants = 242). However, as the study
authors discuss, this finding may be related to unblinded clinicians
who tended to favour prednisolone over dexamethasone and were
more inclined to prescribe additional steroids for those in the dex-
amethasone intervention group, reducing our confidence in this
result.
Lung function tests
Some included studies reported lung function test results, predom-
inantly peak expiratory flow rates (PEFRs) and forced expiratory
volume in one second (FEV1), but overall these studies did not
identify a conclusive benefit of one steroid regimen over another.
PEFR: adults
Two studies of adult participants that compared longer courses ver-
sus shorter courses of prednisolone (Jones 2002; O’Driscoll 1993)
reported trough PEFR. Although a combined analysis of results
of these two studies did not suggest differences between treatment
regimens, the confidence intervals did not rule out a perceivable
difference between trial arms (Analysis 1.6; MD -4.81, 95% CI -
45.82 to 36.20; participants = 79; I2 = 0%). Viska 2008, a con-
ference abstract, randomised adult participants to higher- versus
lower-dose prednisolone and reported PEFR at four weeks but
did not reveal total ’n’ for each group and reported no variance,
so we were unable to include this study in the quantitative syn-
thesis. Mean PEFR at four weeks (two weeks post treatment) for
the higher-dose group was 272.89 L/min, and for the lower-dose
group 296.11 L/min.
FEV1: adults
Two small studies of stable (higher total dose) versus tapered (lower
total dose) prednisolone, given for the same duration (Cydulka
1998; Karan 2002), reported FEV1% predicted at 21 days (exact
timing of the test not specified). Again, although investigators
detected no differences between treatment regimens, we cannot
conclude that the regimens are equivalent because data provided
were insufficient (Analysis 1.7; MD -1.02, 95% CI -4.62 to 2.58;
participants = 41; I2 = 0%); our confidence in this result is further
reduced by the indirectness of treatment regimens used in these
studies and by the unusually small standard deviations reported.
PEFR and FEV1: children
In children, only one study, which compared high-, medium- and
low-dose prednisolone (Langton Hewer 1998), measured FEV1%
predicted (Analysis 3.8) and PEFR% predicted (Analysis 3.9) at
discharge in a small subgroup of participants who were able to
perform these tests. Results were inconsistent (i.e. did not demon-
strate a dose-response relationship) and confidence intervals were
overlapping for all three comparisons (high vs medium, high vs
low and medium vs low) for both outcomes.
All adverse events/side effects
Similarly to serious adverse events, all adverse events were not
frequently reported by the included studies, and when they were
reported, benefit of one regimen over another was not generally
shown.
Adults
Lederle 1987, a study of long tapering (seven weeks) versus short
tapering (sevendays) of prednisolone,was the only study including
adults that reported adverse events. These were defined as ’steroid
20Different oral corticosteroid regimens for acute asthma (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
side effects’, including weight gain, oedema, acne and easy bruis-
ing. Findings favoured a shorter taper but with very wide confi-
dence intervals, which did not exclude the possibility of no dif-
ferences (Analysis 1.9; OR 4.15, 95% CI 0.94 to 18.41; partici-
pants = 43). Of note, many participants likely had COPD with
reversibility and may represent a distinctly different group from
participants in the other included studies. Our confidence in this
result is very low.
Children
In children, only one study of a five- versus three-day course of
prednisolone (Chang 2008) reported all adverse events. Events
were too infrequent to permit conclusions about the relative sa-
fety of a longer course versus a shorter course (Analysis 3.10;
OR 0.67, 95% CI 0.11 to 4.08; participants = 201). Two stud-
ies of higher-dose versus lower-dose prednisolone (Kayani 2002;
NCT00257933) specifically reported recognised steroid side ef-
fects (facial fullness, facial erythema, change in appetite, abdom-
inal pain, diarrhoea, anxiety, euphoria, depression, quiet and re-
served manner, hyperactivity and aggressive behaviour). Langton
Hewer 1998 also specifically reported ’hyperactivity related to
beta-agonist use’, which we combined with findings of the two
aforementioned studies in a meta-analysis. None of themeta-anal-
yses showed clear benefit of one regimen over another. Of note,
analyses of anxiety, hyperactivity and aggressive behaviour demon-
strated high levels of heterogeneity, and many showed substantial
imprecision (Analysis 3.11).
Finally, Cronin 2015, Greenberg 2008 and Qureshi 2001 - all
trials of prednisolone versus dexamethasone - specifically reported
the adverse event of vomiting. Findings favoured dexamethasone,
but with moderate heterogeneity, and the confidence interval did
not exclude the possibility of no difference or modest benefit with
use of prednisolone (Analysis 4.10; OR 3.05, 95% CI 0.88 to
10.55; participants = 867; I2 = 53%).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Adults: prednisolone compared with dexamethasone for acute asthma
Patient or population: adults with an acute exacerbat ion of asthma
Setting: inpat ient or community
Intervention: prednisolone
Comparison: dexamethasone
Duration: 2 weeks
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with dexametha-
sone
Risk with prednisolone
Re-admission during
follow-up period
29 per 1000 10 per 1000
(1 to 93)
OR 0.35
(0.04 to 3.47)
200
(1 RCT)
⊕©©©
Very lowa,b
Asthma symptoms
Returned to normal ac-
t ivit ies within 3 days
901 per 1000 800 per 1000
(634 to 902)
OR 0.44
(0.19 to 1.01)
191
(1 RCT)
⊕⊕©©
Lowb,c
New exacerbation dur-
ing follow-up period
Any ED visit af ter dis-
charge
48 per 1000 63 per 1000
(19 to 184)
OR 1.32
(0.39 to 4.47)
200
(1 RCT)
⊕©©©
Very lowa,b
New exacerbation dur-
ing follow-up period
Unscheduled
visit to primary health-
care provider
29 per 1000 52 per 1000
(13 to 191)
OR 1.85
(0.43 to 7.96)
200
(1 RCT)
⊕©©©
Very lowa,b
* Risk in the intervention group (and its 95% conf idence interval) is based on assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI)
CI: Conf idence interval; ED: emergency department; OR: Odds rat io; RCT: randomised controlled trial; RR: Risk rat io
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GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to the est imate of ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of ef fect but may be substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aOnly 1 study contributed to this outcome with very few events reported in total, result ing in an imprecise est imate with
conf idence intervals including both important harms and benef its of either regimen. Downgraded twice for imprecision
bOnly contribut ing study judged to be at high risk of attrit ion bias because of post-randomisat ion exclusions and large
numbers lost to follow-up. Downgraded once for risk of bias
cOnly 1 study contributed to this outcome with imprecise est imate and conf idence intervals not completely excluding the
possibility of no dif ferences. Downgraded once for imprecision
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Children: higher dose/ longer course compared with lower dose/ shorter course for acute asthma
Patient or population: children with an acute exacerbat ion of asthma
Setting: inpat ient or community
Intervention: higher dose/ longer course of oral steroids
Comparison: lower dose/ shorter course of oral steroids
Duration range: 1 to 4 weeks
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with lower dose/
shorter course
Risk with higher dose/
longer course
Re-admission during
follow-up period
Higher- vs lower-dose prednisolone Not est imable 98
(1 RCT)
⊕©©©
Very lowa,b,c
Only one 3-arm study
(Langton Hewer 1998)
contributed events to
this anal-
ysis. Two lower-dose
arms pooled for this
outcome. OR 1.55 (0.24
to 9.78) favouring lower
dose
Not pooled Not pooled
Longer vs shorter course prednisolone OR 0.33
(0.01 to 8.28)
201
(1 RCT)
⊕⊕©©
Lowc
10 per 1000 3 per 1000
(0 to 76)
Longer vs shorter course dexamethasone OR 2.22
(0.19 to 25.27)
100
(1 RCT)
⊕©©©
Very lowc,d
19 per 1000 42 per 1000
(4 to 331)
Asthma symptoms
Symptom f ree by 7 days
Longer vs shorter course prednisolone OR 1.22
(0.67 to 2.19)
201
(1 RCT)
⊕⊕⊕©
Moderatee
One other study (
Langton Hewer 1998)
randomising 98 chil-
dren to high- vs
medium- vs low-dose
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prednisolone reported
clinical asthma score at
discharge. Small dif f er-
ences in scores were
reported with uncertain
clinical importance and
no consistent dose-re-
sponse ef fect
307 per 1000 351 per 1000
(229 to 492)
Serious adverse events Longer vs shorter course prednisolone Not est imable 201
(1 study)
No events occurred in
either trial arm
0 per 1000 0 per 1000
(0 to 0)
New exacerbation dur-
ing follow-up period
Oral cort icosteroids
prescribed
Higher- vs lower-dose prednisolone OR 1.38
(0.25 to 7.47)
231
(2 RCTs)
⊕⊕©©
Lowf
17 per 1000 24 per 1000
(4 to 116)
Longer vs shorter course prednisolone OR 0.61
(0.19 to 1.94)
201
(1 RCT)
⊕⊕⊕©
Moderatee
79 per 1000 50 per 1000
(16 to 143)
Longer vs shorter course dexamethasone OR 0.24
(0.05 to 1.19)
100
(1 RCT)
⊕⊕©©
Lowd,g
154 per 1000 42 per 1000
(9 to 178)
New exacerbation dur-
ing follow-up period
Unscheduled visit to
healthcare provider
Longer vs shorter course dexamethasone OR 2.17
(0.67 to 7.01)
100
(1 RCT)
⊕©©©
Very lowc,d
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96 per 1000 188 per 1000
(67 to 427)
Lung function tests
FEV1% predicted at dis-
charge
High vs medium vs low dose - 34
(1 study)
This outcome includes
only 1 small study (
Langton Hewer 1998)
in which a subset of
part icipants were able
to perform PFTs. Re-
ported between-group
dif ferences were small
and of uncertain clin-
ical importance with
no consistent dose-re-
sponse ef fect- -
All adverse events Longer vs short course prednisolone OR 0.67
(0.11 to 4.08)
201
(1 RCT)
⊕⊕⊕©
Moderatee
30 per 1000 20 per 1000
(3 to 111)
* Risk in the intervention group (and its 95% conf idence interval) is based on assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI)
CI: Conf idence interval; FEV1: f orced expiratory volume in 1 second; OR: Odds rat io; PFTs: pulmonary funct ion tests; RCT: randomised controlled trial; RR: Risk rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to the est imate of ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of ef fect but may be substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aOnly 1 study contributed events to this outcome and was assessed to be at high risk of attrit ion bias because of unbalanced
drop-out f rom intervent ion arms. Downgraded once for risk of bias
bThe study contribut ing events had 3 dif ferent dose arms, 1 of which is outside the current dosing guidelines. Two other
studies reported no events, but intervent ion involved much higher doses of prednisolone. Downgraded once for indirectness
cOnly 1 study contributed to this analysis. Imprecise est imate with conf idence intervals including possibility of important
harms or benef its. Downgraded twice for imprecision
2
6
D
iffe
re
n
t
o
ra
l
c
o
rtic
o
ste
ro
id
re
g
im
e
n
s
fo
r
a
c
u
te
a
sth
m
a
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
6
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
dOnly contribut ing study considered at high risk of bias in mult iple domains. Downgraded once for risk of bias
eOnly 1 study contributed to this outcome, result ing in imprecise est imate and conf idence intervals including the possibility
of important harms or benef its. Downgraded once for imprecision
f Only 2 studies contributed to this outcome with few events, result ing in imprecise est imate and wide conf idence intervals
including the possibility of important harms or benef its. Downgraded twice for imprecision
gOnly 1 study contributed to this outcome, result ing in imprecise est imate, which does not exclude the possibility of no
dif ference. Downgraded once for imprecision
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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Children: prednisolone compared with dexamethasone for acute asthma
Patient or population: children with acute exacerbat ion of asthma
Setting: inpat ient or community
Intervention: prednisolone
Comparison: dexamethasone
Duration range: 1.5 to 3 weeks
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with dexametha-
sone
Risk with prednisolone
Admission at initial
presentation
116 per 1000 124 per 1000
(89 to 172)
OR 1.08 (0.74 to 1.58) 1007
(3 RCTs)
⊕⊕©©
Lowa,b
Re-admission during
follow-up period
22 per 1000 10 per 1000
(3 to 29)
OR 0.44 (0.15 to 1.33) 985
(3 RCTs)
⊕⊕©©
Lowa,b
Asthma symptoms
scores
Pulmonary Index Score
(PIS); Pat ient Self As-
sessment Score (PSAS)
; Paediatric Respira-
tory Assessment Mea-
sure (PRAM)
Not pooled Not pooled - 328
(2 RCTs)
⊕©©©
Very lowc,d,e,f
Altamimi 2006 reported
PIS and PSAS
Cronin 2015 reported
PRAM (we extracted
the result , which ex-
cluded re-enrolments)
No between-group dif -
ferences were detected
Asthma symptoms
Per-
sistent cough, wheeze,
chest t ightness, night-
t ime wakening and dif -
f iculty maintaining nor-
mal act ivit ies
Not pooled Not pooled - 533
(1 RCT)
The number of peo-
ple experiencing these
symptoms at day 10
was not found to be sig-
nif icant ly dif f erent be-
tween the 2 intervent ion
arms
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Serious adverse events Not pooled Not pooled Not est imable 255
(2 studies)
No events were re-
ported in either study
New exacerbation dur-
ing follow-up period
Unscheduled visit to
healthcare provider
97 per 1000 83 per 1000
(55 to 126)
OR 0.85 (0.54 to 1.34) 981
(4 RCTs)
⊕⊕©©
Lowa,b
* Risk in the intervention group (and its 95% conf idence interval) is based on assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI)
CI: Conf idence interval; OR: Odds rat io; RCT: randomised controlled trial; RR: Risk rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to the est imate of ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of ef fect but may be substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aThe 2 studies contribut ing most events to this outcome were considered to be at high or unclear risk of select ion (Qureshi
2001) and performance and detect ion bias (Cronin 2015; Qureshi 2001). In addit ion, Cronin 2015 allowed 19 part icipants
to enrol more than once in the study. Downgraded once for risk of bias
bConf idence intervals include possible harms or benef its of either intervent ion. Downgraded once for imprecision
cThe pulmonary index score may lack rigorous evaluat ion, so clinical interpretat ion of this score is lim ited. Downgraded once
for indirectness
dConf idence intervals for PIS and PSAS include no dif ference, but we are unsure whether either end of the conf idence intervals
includes a clinically important ef fect. Downgraded once for imprecision
eThe PSAS score has been adapted f rom National Inst itute of Health guidelines and may lack rigorous evaluat ion, so clinical
interpretat ion is lim ited. Downgraded once for indirectness
f We were unable to combine the results of these dif ferent scales. Downgraded once for inconsistency
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D I S C U S S I O N
Summary of main results
This review includes 18 studies that randomised a total of 2438
participants to comparisons of interest. Nine studies recruited only
children, and seven only adults. Two studies did not report the
age range of participants; we assumed one to be a study in adults,
as the steroid doses described were consistent with treatment of
adults (Aboeed 2014); the other was presented as a conference
abstract, which did not contribute to the quantitative synthesis
(Viska 2008). The included studies assessed higher versus lower
doses of prednisolone (n = 4); longer versus shorter courses of
prednisolone (n = 3) or dexamethasone (n = 1); tapered versus non-
tapered courses of prednisolone (n = 4); and prednisolone versus
dexamethasone (n = 6). The varied interventions and outcomes
reported limited the number of meaningful meta-analyses that we
could perform.
Overall, we did not find convincing evidence of a difference in
outcomes between a higher dose or a longer course and a lower
dose or a shorter course prednisolone or dexamethasone, or be-
tween prednisolone and dexamethasone. For two of our primary
outcomes - hospital admission and serious adverse events - events
were too infrequent to allow a conclusion about the superiority of
one treatment over the other, or about their equivalence. Included
studies reported asthma symptoms several differentways and rarely
used validated scales, again limiting the conclusions that we could
reach. Secondary outcome meta-analysis was similarly hampered
by heterogeneity among the interventions and outcomes measures
used.
Included studies generallywere of reasonablemethodological qual-
ity, but generation of the randomisation sequence, allocation pro-
cedures and blinding of outcome assessors were frequently inad-
equately described. In six studies, participants were not blinded
to their group allocation (Figure 2). Most outcomes in the review
were assessed to be of low or very low quality, meaning that we are
not confident in the effect estimates. The predominant reason for
downgradingwas imprecision, but indirectness and risk of bias also
reduced our confidence in some estimates (Summary of findings
for the main comparison; Summary of findings 2; Summary of
findings 3; Summary of findings 4).
Overall completeness and applicability of
evidence
Although oral steroids are commonly used for asthma exacerba-
tions worldwide, we identified only 18 studies of variable method-
ological quality that met our inclusion criteria.
Management of asthma exacerbations differs internationally, af-
fecting the definition of a ’high-’ or ’low-’ dose regimen, or a ’short’
or ’long’ course. Some guidelines define a recommended range for
the course of steroids (GINA 2015; NAEPP 2007); others em-
phasise that courses should be no less than five days but keep the
length otherwise open-ended (BTS/SIGN 2014). Regimens rec-
ommended by guidelines are likely to differ in cost and possibly
in adherence, leaving practitioners in doubt about the preferred
plan.
The recommendation to use a low or high dose or a short or long
course might be understood differently in different countries if
attention is not paid to the individual studies from which the evi-
dence has been drawn. Also, practice has changed over time. The
dates of studies included in this review range from 1987 (Lederle
1987) to 2015 (Cronin 2015), and what was considered a ’shorter
regimen’ in an earlier study might be considered a ’longer regimen’
today. Indeed, although many of the included studies compared
currently used regimens, others used uncommon doses or lengths
of treatment in one or both trial arms that are not recommended
by current guidelines and are not commonly used in practice to-
day (Cydulka 1998; Hasegawa 2000; Karan 2002; Lederle 1987;
O’Driscoll 1993; Viska 2008), limiting the applicability of evi-
dence derived from these trials.
In terms of choice of steroid, prednisolone is recommended as first-
line in all guidelines, whether for adults or for paediatric patients,
and the evidence presented in this review is not strong enough to
indicate whether the usual second-line option, dexamethasone, is
better or worse than prednisolone. Of note, this review did not
consider other head-to-head steroid comparisons, as the primary
objective was to assess the evidence for different doses and dura-
tions. Indeed, several included studies, which compared dexam-
ethasone versus prednisolone, gave very similar total steroid doses
within each intervention arm (e.g. Aboeed 2014;Greenberg 2008;
Kravitz 2011; Table 1) and so addressed a slightly different ques-
tion. This may explain why researchers detected little difference
between arms. We did not combine these studies with any that
assessed a different total dose or duration of the same steroid.
An important question that is addressed by some of the included
studies (Aboeed 2014; Altamimi 2006; Cronin 2015; Cydulka
1998; Karan 2002; Lederle 1987; Qureshi 2001) is whether du-
ration or complexity of the regimen affects participant adherence.
Potential benefits of a longer treatment course risk may be un-
derestimated if adherence is suboptimal compared with a shorter
or less complex course. In clinical practice, this may be a factor
that affects an individual clinician’s choice, depending on the be-
haviour and needs of a particular patient. For example, a clinician
might choose a shorter course or the option with the fewest daily
doses for patients who have trouble adhering to medications. This
may be particularly true for the head-to-head comparison of dex-
amethasone versus prednisolone described in this review, wherein
factors such as palatability may have resulted in differential adher-
ence to treatment regimens. This review did not seek to address
this question, but it may be an important topic for future research.
In addition, almost all of the included studies recruited partic-
ipants from an emergency department setting, which limits the
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applicability of our findings to people with asthma exacerbations
who present to a primary care provider.
We had planned to perform subgroup analyses to explore whether
background asthma severity or severity of the exacerbation was an
important effect modifier. However, this was not possible, as this
information was not consistently reported by the included studies,
and heterogeneity of the studies limited meta-analysis.
Quality of the evidence
We assessed the quality of the evidence presented in this review ac-
cording to theGRADE (Grades of Recommendation, Assessment,
Development and Evaluation Working Group) criteria (Higgins
2011) using GRADEpro software (GRADEpro GDT) and pre-
sented these assessments in the ’Summary of findings’ tables.
Summary of findings for the main comparison presents a higher
dose/longer course versus a lower dose/shorter course of oral
steroids in adults; Summary of findings 2 presents prednisolone
versus dexamethasone in adults; Summary of findings 3; presents
a higher dose/longer course versus a lower dose/shorter course
of oral steroids in children; and Summary of findings 4 presents
prednisolone versus dexamethasone in children. We assessed most
outcomes to be of low or very low quality, meaning that we have
limited confidence in the estimates.
We downgraded all outcomes at least once for imprecision, reflect-
ing the small size of most of the included studies and the limited
pooling that we were able to perform. Many effect estimates in-
cluded a potentially important harm or benefit from either inter-
vention, particularly for outcomes in which events were rare, such
as admission to hospital or new exacerbations during the follow-
up period.
We also downgraded several outcomes because of concerns about
possible performance and detection bias in the contributing stud-
ies (Cronin 2015; Ghafouri 2010; Karan 2002; Qureshi 2001),
uncertainty about allocation procedures (Qureshi 2001) or attri-
tion bias (Ghafouri 2010; Kravitz 2011; Langton Hewer 1998).
Indirectness was a concern for outcomes contributed to by studies
that used an intervention not currently used in common prac-
tice (Lederle 1987; Viska 2008) or that recruited a study sam-
ple likely to include many participants with co-morbid COPD
(Lederle 1987). We downgraded other outcomes for indirectness,
as we had concerns about the rigorous validation of the measure-
ment scales used (Altamimi 2006).
We did not suspect publication bias for any of the outcomes as-
sessed. Pooled results appeared consistent, with low heterogene-
ity for almost all outcomes, likely reflecting our circumspect ap-
proach to combining data for which treatments, participants and
underlying clinical questions were not similar enough for pooling
to make sense.
Potential biases in the review process
We followed standard procedure according to theCochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011) to min-
imise bias in the review process. We performed a comprehensive
search and think it unlikely that we failed to identify relevant
studies. Two review authors independently screened the search,
extracted study characteristics, and spot-checked them for accu-
racy; and independently extracted all outcomes data, then checked
them against the original report. Two or more review authors inde-
pendently assessed risk of bias , showing a high level of agreement.
These review authors resolved a few discrepancies by discussion,
carried out GRADE assessments and achieved consensus by dis-
cussion.
However, our approach to the analysis required some flexibility,
as we were unable to fully anticipate the nature of the outcome
data that we would find. The precise comparisons used were in-
evitably performed post hoc as a result, and this introduced the
risk of a data-led analysis. We believe we mitigated for this risk
by extensively discussing different approaches to the analysis and
by seeking the independent opinion of the contact editor for the
review.
Agreements and disagreements with other
studies or reviews
Several systematic reviews have been published that address the
questionof themost effective dose of oral steroids for exacerbations
of asthma. An ’umbrella review’ (Krishnan 2009) concluded that
doses of corticosteroids in excess of 50 to 100 mg per day offer no
advantage over lower doses, and that a non-tapering course given
over five to 10 days is adequate for most patients. Although we
did not consider the evidence presented in this review to be of
sufficient quality to suggest that giving a dose over 50 to 100 mcg
per day confers an advantage, we would agree that high doses have
not generally provedmore effective than lower doses. Furthermore,
a daily dose of 50 to 100 mg exceeds the dose recommended by
some current guidelines (BTS/SIGN 2014), and a five- to 10-day
range still leaves uncertainty for practitioners, which is especially
important as many patients report that they experience unpleasant
side effects while taking steroids.
An earlier Cochrane review (Manser 2001) assessed the evidence
for the optimal dose of steroids, given by any route, for patients
with severe asthma exacerbations requiring hospitalisation. This
review also concluded that no evidence indicated that higher doses
were associated with better outcomes or indeed with more adverse
events. However, Manser 2001 included a cohort of patients with
much more severe disease, and the doses given in the included
studies far exceeded those assessed in this review, for example, high
dose was considered greater than 360 mg per day methylpred-
nisolone-equivalent, medium dose between 80 and 360 mg and
low dose 80 mg or less.
31Different oral corticosteroid regimens for acute asthma (Review)
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Ameta-analysis conducted to address the question of whether dex-
amethasone is an equivalent alternative treatment to prednisolone
in children with acute asthma (Keeney 2014) included six studies,
three of which are included in the current review. The additional
three studies included in Keeney 2014 used dexamethasone given
intramuscularly; therefore we excluded them. We also included
Cronin 2015, published after Keeney 2014. However, the overall
conclusions of Keeney 2014 are similar to ours; in terms of efficacy,
one drug does not appear to be superior to the other. Study au-
thors also note that dexamethasone may be associated with fewer
episodes of vomiting and better adherence to prescribed therapy,
but this is perhaps to be expected in a review that includes studies
that used the intramuscular route for dexamethasone administra-
tion. We were unable to locate a systematic review that addressed
this question in adult patients.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The evidence is not strong enough for review authors to con-
clude that shorter or lower-dose regimens are generally less effec-
tive than longer or higher-dose regimens, or indeed that the latter
are associated with more adverse events. In particular, important
outcomes, such as serious adverse events and hospitalisations, oc-
curred too infrequently for us to be certain whether one steroid
regimen is superior to another. Changes to current practice should
be supported by larger, well-designed trials, and clinicians should
continue to consider an individual patient’s circumstances when
choosing an oral corticosteroid regimen. Varied study design and
outcome measures limited the number of meta-analyses that we
could perform. Some studies provided steroid regimens that are
not recommended by major national or international guidelines,
limiting the applicability of study findings to current practice.
Implications for research
We were somewhat surprised by the relative paucity of evidence
addressing this question. Larger studies will be required to de-
termine whether differences between regimens can be found for
rare, but important, outcomes such as serious adverse events and
hospitalisations. Adherence to the prescribed regimen and palata-
bility may also be important outcomes to include, to allow clini-
cians to continue to tailor treatment to individual patient circum-
stances. Triallists should aim to use validated measurement scales
and should ensure that treatment regimens are relevant to current
practice. In addition, we found few studies in which participants
were recruited in a community setting - where many prescriptions
for oral steroids are supplied. Therefore, it is unclear how applica-
ble our findings would be in this setting. We suggest that future
trials could be conducted in this setting to improve the generalis-
ability of findings of future reviews.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Aboeed 2014
Methods Design: randomised trial; blinding not described
Duration: corticosteroid treatment continued for 2-5 days depending on allocation;
participants followed up to 30 days (trial still ongoing)
Setting: treatment initiated in the ED and completed at home; trial carried out in USA
Participants Population: 58 individuals with acute exacerbation of asthma randomised to receive
prednisolone or dexamethasone (total number allocated to each group not reported)
Age: not reported
Inclusion criteria: participants with an acute asthma exacerbation
Exclusion criteria: not reported
Percentage withdrawn: not reported
Allowed medication: “both arms received the same medical/pharmacologic interven-
tions”
Disallowed medication: not reported
Interventions Prednisolone group: 40 mg prednisolone once daily for 5 days (200 mg total dose
prednisolone equivalent)
Dexamethasone group: 16 mg dexamethasone once daily for 2 days (213 mg total dose
prednisolone equivalent)
Outcomes ED revisit rates, symptom resolution (defined as participant return to baseline or no
limitation in daily activities), compliance with therapy
Notes Type of publication: conference abstract; interim report of an ongoing study. Study
authors contacted on 21 September 2015 for further information; at time of publication,
no response received
Funding: St. Joseph’s Regional Medical Center
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient details to make judgement
Allocation concealment (selection bias) Unclear risk Insufficient details to make judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Insufficient details to make judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient details to make judgement
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Aboeed 2014 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient details to make judgement
Selective reporting (reporting bias) High risk Conference abstract, study incomplete, re-
sults not presented in a way that would
allow inclusion in meta-analysis. Unclear
whether trial was prospectively registered
Other bias Low risk None noted
Altamimi 2006
Methods Design: randomised, double-blind trial
Duration: corticosteroid treatment continued for 1-5 days depending on allocation;
followed up at 5 days and discharged from the study if fully recovered. Follow-up for
those not fully recovered continued for 3 weeks maximum
Setting: treatment initiated in the EDand completed at home; trial carried out inCanada
Participants Population: 134 children with acute exacerbations of asthma randomised to receive
prednisolone (n = 67) or dexamethasone (n = 67)
Age: 2-16 years; median age in the prednisolone group was 5 years and in the dexam-
ethasone group 4 years
Inclusion criteria: children presenting to the ED with a mild to moderate exacerbation
of asthma with a history of≥ 1 prior episode of wheezing or shortness of breath requiring
treatment with salbutamol, mild to moderate exacerbation defined as PIS score < 9 and
PEFR > 60% predicted
Exclusion criteria: signs of severe asthma on presentation (PEFR < 60%, PIS ≥ 10)
; complete recovery after first dose of salbutamol; use of oral steroids in preceding 2
weeks; history of severe asthma exacerbation, including intubation or ICU admission for
asthma, chronic lung disease, heart disease or neurological disorder; psychiatric disorder;
history of acute allergic reaction, active chicken pox or herpes simplex infection
Percentage withdrawn: withdrawal from the prednisolone group was 19.9% and from
the dexamethasone group 16.4%
Allowed medication: salbutamol
Disallowed medication: inhaled corticosteroids
Interventions Prednisolone group: 1 mg/kg prednisolone twice daily for 5 days (maximum 30 mg
per dose; total dose based on a 20 kg child 200 mg prednisolone equivalent)
Dexamethasone group: 0.6 mg/kg dexamethasone as a single dose (maximum 18 mg;
total dose based on a 20 kg child 80 mg prednisolone equivalent)
Outcomes Number of days required formodified patient self assessment sheet (PSAS) score to return
to baseline/PEFR to return to ≥ 80% predicted, adverse events, rescue medication use,
unscheduled ED or family doctor visits, oxygen saturation, vital signs, PIS, participant
compliance
Notes Type of publication: peer-reviewed
Funding:TrudellMedical contributed peak flowmeters; funding otherwise not reported
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Altamimi 2006 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Consenting participants were assigned via
prepared, sealed, computer-generated ran-
domisation cards to receive dexamethasone
or prednisolone
Allocation concealment (selection bias) Low risk Consenting participants were assigned via
prepared, sealed, computer-generated ran-
domisation cards to receive dexamethasone
or prednisolone
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The pharmacy, with no involvement of
study investigators, prepared randomisa-
tion cards and blended study medications
to look and taste identical. Placebomedica-
tion was blended to mimic study medica-
tions. Participants receiving the single dose
of dexamethasone were given placebomed-
ication to complete a 5-day course, as per
prednisolone regimen
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants, personnel and investigators
were blinded to assignment and contents
of study medication bottles
Incomplete outcome data (attrition bias)
All outcomes
Low risk Drop-out balanced and < 20% in both in-
tervention arms; all withdrawals accounted
for in study flow diagram
Selective reporting (reporting bias) Low risk All stated outcomes reported numerically
apart from number of salbutamol adminis-
trations at home, which is reported narra-
tively in the study report.However, unclear
whether trial was prospectively registered
Other bias Low risk None noted
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Chang 2008
Methods Design: randomised (stratified by age and site of enrolment), double-blind trial
Duration: corticosteroid treatment continued for 3-5 days depending on allocation;
follow-up continued to 28 days, or re-admission to hospital, whichever occurred first
Setting: treatment initiated in ED and completed at home; trial carried out in ED of 3
hospitals in Queensland, Australia
Participants Population: 201 children with acute exacerbation of asthma randomised to receive a
longer course (n = 100) or a shorter course (n = 101) of prednisolone
Age: 2-15 years; mean age (SD) in prednisolone longer course group was 4.7 (3.1) years
and in shorter course group 4.8 (2.8) years
Inclusion criteria: children presenting with an acute exacerbation of asthma during or-
dinary hours (07:30-17:00) to the ED of 3 Queensland hospitals, but not hospitalised.
Asthma was defined as recurrent (> 2) episodes of wheeze and/or dyspnoea with a clin-
ical response (decreased respiratory rate and work of breathing) to salbutamol. Asthma
exacerbation was defined as acute deterioration of asthma control requiring treatment
with more than a single dose (> 600 µg via metered dose inhaler and spacer or > 2.5 mg
nebulised) of salbutamol in an hour
Exclusion criteria: underlying respiratory disease (e.g. bronchiectasis), cerebral palsy or
severe neurodevelopmental abnormality, immunodeficiency, previous enrolment in the
study, receivingmaintenance oral corticosteroids, receiving >1dose of oral corticosteroids
before presentation,very severe asthma (status asthmaticus; requiring hospitalisation,
continuous nebulisation and/or intravenous salbutamol)
Percentage withdrawn:withdrawal from longer course groupwas 15%and from shorter
course group 20.1%
Allowed medication: salbutamol
Disallowed medication: additional course of oral corticosteroids
Interventions Prednisolone longer course group: 1 mg/kg prednisolone daily for 5 days (maximum
dose 50 mg; total dose based on 20 kg child 100 mg prednisolone equivalent)
Prednisolone shorter course group: 1 mg/kg prednisolone daily for 3 days (maximum
dose 50 mg; total dose based on 20 kg child 60 mg prednisolone equivalent)
Outcomes Proportion of children without asthma symptoms, as scored on validated diary cards
on day 7 (children were considered still symptomatic if their average asthma score for
the day was 0.2), PACQLQ scores on days 7 and 14, average asthma scores as provided
on asthma and cough diary cards on days 5, 10 and 14, recurrence of exacerbation,
unscheduled re-presentation to a health facility
Notes Type of publication: peer-reviewed
Funding: Asthma Foundation of Queensland and the Royal Children’s Hospital Foun-
dation. All placebo and some active medication were donated by Aspen Pharmacare
Study identifier: Australian Clinical Trials Registry; ACTRN012605000305628
Risk of bias
Bias Authors’ judgement Support for judgement
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Chang 2008 (Continued)
Random sequence generation (selection
bias)
Low risk Children were randomised within strata of
age (< 6 or 6-15 years) and site of enrol-
ment. On recruitment, children were allo-
cated to the next treatment regimen on a
list (randomised by permutated block de-
sign at a remote site)
Allocation concealment (selection bias) Low risk A sticker obscured the next treatment
group and was removed only after enrol-
ment (concealed treatment allocation)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Children received oral prednisolone for 5
days or prednisolone for 3 days, followed
by placebo (a liquid with similar taste) for 2
days. Trial medications were stored in iden-
tical bottles and were labelled A and B. The
study team (other than the pharmacist, who
was not involved in data collection), chil-
dren and parents were blinded to trial med-
ications
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Study team (other than the pharmacist,
who was not involved in data collection),
children and parents were blinded to trial
medications. Code was revealed only af-
ter study and statistical analysis were com-
pleted
Incomplete outcome data (attrition bias)
All outcomes
Low risk Drop-out balanced and 15%-20% in both
intervention arms; all withdrawals ac-
counted for and ITT data analysis per-
formed for primary outcomes
Selective reporting (reporting bias) Low risk All stated outcomes reported; trial prospec-
tively registered
Other bias Low risk None noted
Cronin 2015
Methods Design: randomised, open-label trial
Duration: corticosteroid treatment continued for 1-3 days with follow-up for 2 weeks
Setting: treatment initiated in the ED and completed at home; trial carried out in Ireland
Participants Population: 250 children with an acute exacerbation of asthma presenting to the ED
at a hospital in Dublin were randomised to a 3-day course of prednisolone (n = 123)
or a 1-day (single dose) course of dexamethasone (n = 127). NB: 19 participants were
enrolled more than once during the course of the study; in total, 226 individual children
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Cronin 2015 (Continued)
participated
Age: 2-16 years; mean age (SD) in prednisolone group was 5.8 (3.22) years and in
dexamethasone group 5.7 (3.52) years
Inclusion criteria: children aged 2-16 years with a history of asthma who presented
to the ED with an acute asthma exacerbation. A history of asthma was defined as ≥ 1
previous episode of beta-2-agonist-responsive wheeze or previous diagnosis of asthma,
made by a paediatrician or clinician of comparable experience. An exacerbation of asthma
was defined as acute asthma that prompts ED assessment, with any or all of the following
clinical features: dyspnoea, wheeze, acute cough, increased work of breathing, increased
requirement for beta-2-agonist from baseline use or SaO2 < 95%
Exclusion criteria: children with critical or life-threatening asthma exacerbation, active
varicella or herpes simplex infection; documented concurrent infection with respiratory
syncytial virus; temperature > 39.5°C; use of oral or intravenous corticosteroids in pre-
vious 4 weeks; concurrent stridor, galactose intolerance, Lapp-lactase deficiency or glu-
cose galactose malabsorption, history of tuberculosis exposure or significant co-morbid
disease
Percentage withdrawn: withdrawal from prednisolone group 3.2% and from dexam-
ethasone group 0.8%
Allowed medication: standard therapy according to guidelines and at the discretion of
the treatment physician, including inhaled beta-2-agonist and ICS (if participant was
already taking this at baseline)
Disallowed medication: not reported
Interventions Prednisolone group: 1 mg/kg once daily for 3 days (maximum dose 40 mg; total dose
based on 20 kg child 60 mg prednisolone equivalent)
Dexamethasone group: 0.3 mg/kg once daily for 1 day (maximum dose 12 mg; total
dose based on 20 kg child 40 mg prednisolone)
Outcomes Primary outcome: Pediatric Respiratory Assessment Measure (PRAM) score at day 4
Secondary outcomes: change in PRAM score from ED arrival to follow-up, PRAM
score at ED discharge, hospital admission fromEDon day 1, ED length of stay, unsched-
uled visits to healthcare provider for asthma or respiratory symptoms within 14 days of
study enrolment, re-admission to hospital after discharge and within 14 days of study
enrolment, administration of additional systemic corticosteroids within 14 days of study
enrolment, number of salbutamol therapies administered after enrolment, incidence of
vomiting within 30 minutes of study medication, school days and parental workdays
missed and days of restricted activity
Notes Type of publication: peer-reviewed
Funding: National Children’s Research Centre, Our Lady’s Children’s Hospital, Crum-
lin, Dublin, Ireland
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “We used a randomization design achieved
by generating numeric codes in random
permuted blocks of 12 subjects. The ran-
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domization process was designed by the
study statistician and was kept in a locked
storage cupboard in the hospital’s phar-
macy department”
Allocation concealment (selection bias) Low risk “The recruiting clinician took the next
available numbered envelope from the pre-
randomized pack of study envelopes con-
tained in a locked storage cupboard in the
ED. This envelope contained the subject
identification number of each enrolled pa-
tient and stated to which treatment arm
they were assigned”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk This was an open-label study; participants
and personnel were aware of assignment
status; this may have affected their perfor-
mance
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk This was an open-label study. The PRAM
outcome “was performed by a senior physi-
cian blinded to treatment allocation. Pa-
tients and families were instructed not to
reveal treatment allocation to the clinician
measuring the PRAM score on day 4.” For
other outcomes, such as additional courses
of steroids or visits to HCP, the study is at
higher risk. Overall, we rated this risk as
unclear
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low and balanced drop-out, and all par-
ticipants accounted for. Intention-to-treat
analysis performed
Selective reporting (reporting bias) Low risk Prospectively registered trial and published
protocol. Some planned outcomemeasures
were not clearly reported (e.g. compliance,
costs), but these were not of interest in this
review
Other bias Unclear risk 19 participants were enrolled more than
once during the course of the study. With
the exception of the 4-day PRAM score,
it is unclear from the report whether some
participants contributed more than once to
secondary outcomes
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Methods Design: randomised, double-blind trial
Duration: corticosteroid treatment continued for 8 days, with follow-up continuing to
3 weeks
Setting: treatment initiated in the ED and completed at home; trial carried out in USA
Participants Population: 15 adults with an acute exacerbation of asthma were randomised to an 8-
day non-tapering (n = 7) or an 8-day tapering course (n = 8) of prednisolone
Age: 19-50 years; mean age (SD) in non-tapering group was 24.1 (5.0) years and in
tapering group 32.0 (8.5) years
Inclusion criteria: Participants 19-50 years of age with acute asthma exacerbation pre-
senting to the ED but judged well enough to be discharged from the ED were recruited.
Participants were judged suitable for discharge by the attending physician if they exhib-
ited complete relief of wheezing or improvement in FEV1 to≥ 70% predicted, or if they
reported significant subjective improvement to near baseline
Exclusion criteria: participants with history of chronic obstructive pulmonary disease,
acute congestive heart failure, pneumonia, pneumothorax or any other acute pulmonary
disease, such as lung cancer, tuberculosis or sarcoidosis, that might confound the results;
patients already using inhaled or oral steroids, those requiring long-term steroid use, as
defined by daily steroid use, those who had required steroids within 2 weeks of admission
to the ED, patients with a history of diabetes or severe hypertension
Percentage withdrawn: withdrawal 0% in both treatment arms
Allowed medication: standard therapy with aerosolised albuterol for a total of 3 doses
Disallowed medication: not reported
Interventions Prednisolone non-taper group: 40 mg/d prednisolone for 8 days (total dose 320 mg
prednisolone equivalent)
Prednisolone taper group: 40 mg/d prednisolone tapering by 5 mg/d over 8 days (total
dose 180 mg prednisolone equivalent)
Outcomes Relapse (defined as return of wheezing or dyspnoea requiring the participant to seek
medical attention within 21 days of initial visit), pulmonary function tests, cosyntropin
stimulation test, compliance with medication, symptoms
Notes Type of publication: peer-reviewed
Funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients…were randomised via a com-
puter-generated randomisation table to 1
of 2 treatment regimens
Allocation concealment (selection bias) Unclear risk No details given
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants in the taper group were given
8 tablets to take each day: 5 mg prednisone
tablets, up to the daily dose of prednisone,
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plus placebo look-alike tablets constituting
the remainder of the 8 tablets
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Trial described as double-blind, although
blinding procedure for outcome assessors
not specifically described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Drop-out not specifically reported, but
endpoint outcome data available for all 15
participants
Selective reporting (reporting bias) Low risk All stated outcomes reported numerically
or narratively. However, unclear whether
trial was prospectively registered
Other bias Low risk None noted
Ghafouri 2010
Methods Design: randomised, open-label trial
Duration: corticosteroid treatment continued for 1-2 days depending on allocation;
follow-up continued until 7 days
Setting: treatment initiated in the ED and completed at home; trial carried out in USA
Participants Population: 125 children presenting with a mild to moderate exacerbation of asthma
were randomised to 2 doses (n = 63) or a single dose (n = 62) of dexamethasone
Age: 2-17 years. Mean age (SD) in longer course group was 5.9 (4.3) years and in shorter
course group 6.0 (3.6) years
Inclusion criteria: children aged 2-17 years who presented to the ED with a mild to
moderate exacerbation of asthma
Exclusion criteria: not reported
Percentage withdrawn: withdrawal from longer course was 23.8% and from shorter
course 16%
Allowed medication: not reported
Disallowed medication: not reported
Interventions Dexamethasone longer course group: 0.6 mg/kg of dexamethasone daily. First dose
on day 1 and second dose on day 3 (maximum dose 16 mg; total dose based on 20 kg
child 160 mg prednisolone equivalent)
Dexamethasone shorter course group: 0.6 mg/kg of dexamethasone as a single dose
(maximum dose 16 mg; total dose based on 20 kg child 80 mg prednisolone equivalent)
Outcomes Time to resolution of symptoms, relapse rate (defined as hospital admission after ED
discharge), unscheduled follow-up visits, additional corticosteroids prescribed within 7
days of ED discharge
Notes Type of publication: conference abstract
Funding: not reported
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient details to make judgement
Allocation concealment (selection bias) Unclear risk Insufficient details to make judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label trial
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open-label trial
Incomplete outcome data (attrition bias)
All outcomes
High risk Unbalanced attrition in intervention
groups (23.8% in longer course group and
16% in shorter course group). Reasons for
drop-out not stated
Selective reporting (reporting bias) Low risk Conference abstract so study details mini-
mal, but prospectively registered. All out-
comes listed in clinical trials record re-
ported
Other bias Low risk None noted
Greenberg 2008
Methods Design: block-randomised, double-blind trial
Duration: corticosteroid treatment continued for 2-5 days depending on allocation;
follow-up continued until 10 days
Setting: treatment initiated in the ED and completed at home
Participants Population: 167 children presenting to the ED with an acute exacerbation of asthma
were enrolled. Numbers randomised to each treatment arm not given. 38 completed in
the prednisolone arm and 51 in the dexamethasone arm
Age: 2-18 years. Median age in prednisolone group 6.2 years and in dexamethasone
group 4.5 years (range 2-18 years for both groups)
Inclusion criteria: children 2-18 years old with a history of asthma (≥ 2 episodes of
wheezing treated with beta-2-adrenergic agonists) who presented to the ED with an
acute exacerbation of their asthma
Exclusion criteria: use of oral steroids in the past month; history of intubation for a
previous asthma exacerbation; varicella exposure in the past 3 weeks; possible foreign
body aspiration; any chronic lung disease (e.g. cystic fibrosis) that would affect the
participant’s treatment; chronic heart, liver or kidney disease; significant respiratory
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distress necessitating airway intervention (e.g. intubation); previous enrolment in this
study; no telephone for follow-up; ≥ 2 episodes of emesis after steroid administration
in the ED
Percentage withdrawn: total exclusion after enrolment 46.7%; numbers excluded from
each arm not reported
Allowed medication: all participants with an acute asthma exacerbation were treated
according to the institution’s asthma clinical care guideline. Children received 3 con-
secutive nebulisers with albuterol and ipratropium bromide. At the time of discharge,
participants received instructions to use their albuterol every 4 hours for 24 hours, then
as needed for symptom relief
Disallowed medication: not reported
Interventions Prednisolone group: 1 mg/kg prednisolone twice daily for 5 days (maximum dose 30
mg; total dose based on 20 kg child 200 mg prednisolone equivalent)
Dexamethasone group: 0.6 mg/kg once daily for 2 days (maximum dose 16 mg; total
dose based on 20 kg child 160 mg prednisolone equivalent)
Outcomes Relapse within 10 days (defined as need for subsequent hospitalisation or unscheduled
visit with a medical provider as the result of continued or worsening asthma symptoms)
, emesis with steroid administration in the ED
Notes Type of publication: peer-reviewed
Funding: supported byGrantNumberMO1-RR00069,General Clinical ResearchCen-
ters Program, National Center for Research Resources, NIH
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block-randomisation (< 7 years and ≥ 7
years) was performed in the hospital phar-
macy
Allocation concealment (selection bias) Unclear risk No details given
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk To ensure double-blinding, the pharmacy
prepared both drugs to look identical
as a white powder in a clear capsule.
Older participants swallowed the capsule,
and younger participants had the powder
mixed with applesauce or pudding for ease
of administration. All capsules, including
placebo, were identical in appearance and
were placed in capsule bubble packets la-
belled dose 1 through 10 to ensure that par-
ticipants in the dexamethasone group re-
ceived the second dose of dexamethasone
as their next dose and then started placebo
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Trial described as double-blind, although
blinding procedure for personnel not
specifically described
Incomplete outcome data (attrition bias)
All outcomes
High risk Approximately half of participants ran-
domised to each treatment did not com-
plete the trial. The most frequent reason
was related tohospital admission. Although
details are given of baseline characteristics
of those who completed and those who did
not, it is unclear how this high level of at-
trition may have affected the findings
Selective reporting (reporting bias) Low risk All started outcomes reported numerically
or narratively, but unclear whether trial was
prospectively registered
Other bias Low risk None noted
Hasegawa 2000
Methods Design: randomised trial; blinding not reported
Duration: oral corticosteroid treatment continued for 1-2 weeks depending on alloca-
tion; follow-up continued until 6 months after initiation of oral steroids
Setting: inpatient; trial carried out in Japan
Participants Population: 20 individuals with an acute exacerbation of asthma were randomised to
2-week course (n = 10) or 1-week course (n = 10) of prednisolone. Oral therapy was
commenced after all participants had received 3 days of intravenous methylprednisolone
(80 mg every 8 hours)
Age: age range not reported; mean age (SD) in the longer course group was 49 (4.5)
years and in the shorter course group 52 (6) years
Inclusion criteria: “asthmatics who were admitted to our hospital due to acute exacer-
bation”
Exclusion criteria: “near fatal attacks, serious complicated disease, pregnancy”
Percentage withdrawn: withdrawal 0% in both treatment arms
Allowed medication: intravenous methylprednisolone, 80 mg every 8 hours for 3 days
after admission, antibiotics, theophylline
Disallowed medication: not reported
Interventions Prednisolone longer course group: 0.5 mg/kg prednisolone once daily for 2 weeks
(maximum doses not given but based on a 70 kg adult total dose would be 490 mg
prednisolone equivalent)
Prednisolone shorter course group: 0.5 mg/kg prednisolone once daily for 1 week
(maximum doses not given but based on a 70 kg adult total dose would be 245 mg
prednisolone equivalent)
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Outcomes MorningPEFR, unscheduled hospital visits due to asthma in the 3months after discharge
Notes Type of publication: peer-reviewed
Funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “They were then randomly allocated into 2
group”; no further details
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Trial not reported as blinded, so assume
open-label
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Trial not reported as blinded, so assume
open-label
Incomplete outcome data (attrition bias)
All outcomes
Low risk Outcome data available for all 20 enrolled
participants
Selective reporting (reporting bias) Low risk All stated outcomes reported, but unclear
whether trial was prospectively registered
Other bias Low risk None noted
Jones 2002
Methods Design: randomised, double-blind trial
Duration: corticosteroid treatment continued for 5-10 days depending on allocation;
follow-up continued until 4-6 weeks
Setting: treatment initiated on an inpatient ward and completed at home; trial carried
out in the UK
Participants Population: 47 adults with an acute exacerbation of asthma were randomised to a longer
course (n = 25) or a shorter course (n = 22) of prednisolone
Age: 16-60 years; mean age (SD) in the longer course group was 29.8 (11.3) years and
in the shorter course group 32.0 (11.0) years
Inclusion criteria: acute adult asthma (peak expiratory flow (PEF) < 65% predicted)
, admission to hospital under the care of designated adult physicians, age 16-60 years,
ability to give informed consent and to maintain a PEF diary for 21 days, use of inhaled
steroid on discharge
Exclusion criteria: major medical illness (such as pneumonia, heart failure, lung cancer
and bronchiectasis), chronic pulmonary disease other than asthma, requirement for
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mechanical ventilation before randomisation, long-term use of oral corticosteroids, use
of nebulised corticosteroids, any recent use of oral corticosteroids before admission
Percentage withdrawn: withdrawal from longer course group 4% and from shorter
course group 9.1%
Allowed medication: All participants were issued a supply of open-label prednisolone
(40 mg for 5 days) for emergency use and were instructed that this should be taken
in the event of deteriorating asthma and recommended to self refer to hospital under
these circumstances. All other asthma treatment was provided at the discretion of the
participant’s personal physician subject to a requirement for all participants to receive
inhaled steroid treatment equivalent to≥ 400 mcg of beclomethasone dipropionate per
day
Disallowed medication: not reported
Interventions Prednisolone longer course group: 40 mg prednisolone once daily for 10 days (total
dose 400 mg prednisolone equivalent)
Prednisolone shorter course group: 40 mg prednisolone once daily for 5 days (total
dose 200 mg prednisolone equivalent)
Outcomes Waking PEF, asthma exacerbations, post-bronchodilator morning PEF, evening PEF,
worst PEF on each day, symptom
scores (overall asthma severity, wheeze severity, cough severity, nocturnal asthma symp-
toms), beta-agonist use
Notes Type of publication: peer-reviewed
Funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were entered in a double-blind
fashion. Randomisation codes (5- or 10-
day course) were sealed in opaque brown
envelopes and shuffled into random order,
then numbered sequentially
Allocation concealment (selection bias) Low risk Randomisation codes (5- or 10-day course)
were sealed in opaque brown envelopes...
the investigator selected the next numbered
envelope for each patient and sent it un-
opened to a non-blinded hospital pharma-
cist with a prescription for “steroid trial
tablets”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Patients were provided 40mg prednisolone
daily for the first 5 days, supplied as 5
mgprednisolone enteric-coated tablets. For
days 6-10, each patient received 8 tablets
per day of enteric-coated prednisolone or
50Different oral corticosteroid regimens for acute asthma (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Jones 2002 (Continued)
an identical placebo tablet
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Trial described as double-blind but specific
details of blinding of outcome assessors not
described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low, balanced drop-out in both groups; 3
participants in total did not complete their
diary cards, but all 3 were reported to have
made a satisfactory recovery and did not re-
quire further course of oral steroids or ad-
mission to hospital
Selective reporting (reporting bias) Low risk All stated outcomes reported, but unclear
whether trial was prospectively registered
Other bias Low risk None noted
Karan 2002
Methods Design: randomised, open-label trial
Duration: corticosteroid treatment continued for 8 days; follow-up continued until 3
weeks
Setting: treatment initiated at outpatient clinic and completed at home; trial carried out
in India
Participants Population: 26 adults with an acute exacerbation of asthma were randomised to a non-
tapering course (n = 13) or a tapering course (n = 13) of prednisolone
Age: 17-70 years; mean age (SD) in non-tapering group 43.9 (12.4) years and in tapering
group 49.2 (12.1) years
Inclusion criteria: aged 16-70 years with an acute asthma exacerbation presenting to
the chest clinic but judged well enough to be discharged (i.e. complete relief of wheez-
ing or improvement in FEV1 to ≥ 70% predicted, or reporting subjective significant
improvement in symptoms to near baseline)
Exclusion criteria: history of chronic obstructive pulmonary disease, acute congestive
heart failure, pneumonia, pneumothorax or any other acute pulmonary disease, such
as lung cancer, tuberculosis or sarcoidosis, etc, that might confound results; asthmatic
patients already using inhaled or oral steroids; long-term steroid use, as defined by daily
steroid use; steroids required within 2 weeks of admission to the chest clinic; history of
diabetes or severe hypertension
Percentage withdrawn: not reported
Allowed medication: other asthma treatments given to both groups as per hospital
policy including beta-2-agonists, sustained release theophylline and inhaled steroids
Disallowed medication: not reported
Interventions Prednisolone non-taper group: 40 mg prednisolone once daily for 8 days (total dose
320 mg prednisolone equivalent)
Prednisolone taper group: 40 mg prednisolone once daily tapering by 5 mg/d over 8
days (total dose 180 mg prednisolone equivalent)
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Outcomes Relapse (defined as return of wheezing or dyspnoea requiring participant to seek medical
attention within 21 days of initial visit), pulmonary function tests, adrenal suppression
as assessed by low-dose ACTH test, compliance with medication
Notes Type of publication: peer-reviewed
Funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as ’randomised’ but insufficient
detail to make judgement about sequence
generation
Allocation concealment (selection bias) Unclear risk No details given
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label trial
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open-label trial
Incomplete outcome data (attrition bias)
All outcomes
Low risk All but 2 participants completed the trial;
outcomes analysed as per ITT principles
(last observation carried forward)
Selective reporting (reporting bias) Low risk All stated outcomes reported, but unclear
whether trial was prospectively registered
Other bias Low risk None noted
Kayani 2002
Methods Design: randomised, double-blind trial
Duration: corticosteroid treatment continued for 5 days with follow-up until 2 weeks
(additional 1-month follow-up in children with reported behavioural symptoms)
Setting: treatment initiated in outpatient clinic or ED and completed at home; trial
carried out in USA
Participants Population:88 childrenwith an acute exacerbationof asthmawere randomised to receive
a higher dose (n = 44) or a lower dose (n = 44) of prednisolone
Age: 2-18 years; mean age (SD) in higher-dose group 6.3 (0.5) years and in lower-dose
group 7.1 (0.6) years
Inclusion criteria: participants aged 2-18 years with mild persistent asthma at baseline
based on National Institutes of Health guidelines (cough, shortness of breath or wheeze
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more than twice a week but less than once a day and similar nighttime symptoms
more than twice a month but less than once a week), those receiving inhaled steroids
(fluticasone 44 mcg (2 puffs) bid) daily and using an albuterol metered dose inhaler
(MDI) as needed. Indications for therapy with oral steroids were an incomplete response
to therapy for acute symptoms with agonists and inhaled steroids. Incomplete response
to therapy was defined as persistence of cough, shortness of breath or wheeze after 3-
agonist treatment via nebuliser over a 1-hour period or lack of response to 3-agonist
treatment of 2 to 4 puffs by MDI over 1 hour
Exclusion criteria: history of chronic lung disease other than asthma; cardiac, liver or
renal disease; attention deficit disorder; previous or current history of psychiatric illness;
use of oral steroids within previous 2 weeks
Percentage withdrawn: withdrawal from both groups 2.2%
Allowed medication: doubled-dose inhaled corticosteroids, as required short-acting
beta-2-agonists
Disallowed medication: oral corticosteroids within preceding 2 weeks
Interventions Prednisolone higher-dose group: 2mg/kg daily prednisolone (given in 2 divided doses)
for 5 days (total maximum daily dose 60 mg; total dose for 20 kg child 200 mg pred-
nisolone equivalent)
Prednisolone lower-dose group: 1 mg/kg daily prednisolone (given in 2 divided doses)
for 5 days (total maximum daily dose 60 mg; total dose for 20 kg child 100 mg pred-
nisolone equivalent)
Outcomes At 5 days: questionnaire asking about most common side effects of steroids, including
facial fullness, facial redness, changes in appetite, abdominal pain, diarrhoea, quiet and
reserved manner, euphoria (excessive happiness), depression, anxiety, hyperactivity with
or without short attention span, aggressive behaviour (responses considered positive only
if symptoms were absent before initiation of steroid therapy); any associated systemic
symptoms; asthma symptom resolution (cough, shortness of breath and wheeze)
Two weeks later: use of additional medications since oral steroid treatment, resolution
of symptoms (cough, shortness of breath and wheeze), relapse (defined as presence or
worsening of cough, wheezing, visits to physician’s office or emergency department or
admission to hospital)
One month later: further follow-up of participants with behavioural symptoms
Notes Type of publication: peer-reviewed
Funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants enrolled in the study were
given 1 of 2 different doses of oral steroids
according to a random allocation chart
based on a table of random numbers. Ran-
domisation code was held by nursing staff
at the asthma centre
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Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Parents, principal investigator and primary
care physician were not told which dose of
oral steroids the child was receiving
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Parents, principal investigator and primary
care physician were not told which dose of
oral steroids the child was receiving, but
outcome assessment may not have been
blinded: “It would have been ideal to have
the interviewer blinded to the study ques-
tions, but every effort was made to avoid
any appearance of bias during the tele-
phone interview”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Only 1 child excluded from analysis in each
arm for protocol violations (1 patient in
group 1 excluded because albuterol dosage
was increased to every 4 hours; 1 patient in
group 2 excluded because inhaled steroid
(fluticasone) dose was increased to 110mcg
and albuterol was used every 4 hours)
Selective reporting (reporting bias) Low risk All stated outcomes reported, although un-
clear whether trial was prospectively regis-
tered
Other bias Low risk None noted
Kravitz 2011
Methods Design: randomised, double-blind trial
Duration: corticosteroid treatment continued for 2-5 days depending on allocation;
follow-up continued until 2 weeks
Setting: treatment initiated in the ED and completed at home; trial carried out in USA
Participants Population: 257 adults with an acute exacerbation of asthma were randomised and
included to receive prednisolone (n = 128) or dexamethasone (n = 129). A total of 28
participants were excluded after randomisation as the result of admission to hospital
Age: 18-45 years; median age (IQR) in prednisolone group 30 (23-38) years and in
dexamethasone group 28 (22-37) years
Inclusion criteria: participants aged 18-45 years, with a diagnosis of asthma for ≥ 6
months and peak expiratory flow rate < 80% predicted
Exclusion criteria: those had received oral corticosteroids in the previous 4 weeks;
patientswho experienced chronic obstructive pulmonary disease, congestive heart failure,
pneumonia or sarcoidosis; those who were pregnant or breastfeeding. Age limit of 45
years was chosen to try to avoid enrolling people with concurrent diagnosis of chronic
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obstructive pulmonary disease. Participants were also excluded if they gave a history
of corticosteroid allergy, tuberculosis, systemic fungal disease, gastritis or diabetes, or if
they were unable to consent to the study or to be available for follow-up. Participants
admitted to the hospital for asthma exacerbation were also excluded from the analysis
Percentage withdrawn: withdrawal from prednisolone group was 25% and from the
dexamethasone group 19%
Allowedmedication:nebulised albuterol and ipratropiumbromide.Other asthma treat-
ments were provided at the discretion of the treating physician
Disallowed medication: oral corticosteroids within preceding 4 weeks
Interventions Prednisolone group: 50 mg once daily for 5 days (total maximum dose 250 mg pred-
nisolone equivalent)
Dexamethasone group: 16 mg daily for 2 days (total maximum dose 213 mg pred-
nisolone equivalent)
Outcomes Number of days required before return to normal daily activities, number of times
albuterol was used per day in the week after ED visit, relapse (defined as repeated ED or
primary care provider visits or admission to hospital forworsening of asthma exacerbation
within 2-week follow-up period)
Notes Type of publication: peer-reviewed
Funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A computerised randomisation table main-
tained by the pharmacy department was
used to assign participants to 1 of 2 treat-
ment arms
Allocation concealment (selection bias) Unclear risk No specific details
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Patients in the prednisone group received
5 medication packets labelled 1 through 5,
each containing 60 mg of prednisone. Pa-
tients in the dexamethasone group received
5 identical medication packets; the first 2
contained 16 mg of oral dexamethasone in
packets 1 and2,with placebodoses in pack-
ets 3 through 5. Medications and placebo
doses were prepared in identical capsules by
the hospital’s pharmacy department, so that
neither the treating emergency physician
nor the enrolling research staff could dis-
cern which study medication was adminis-
tered
55Different oral corticosteroid regimens for acute asthma (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Kravitz 2011 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Study described as double-blind but only
blinding of enrolling staff specifically de-
scribed; blinding of outcome assessors not
described
Incomplete outcome data (attrition bias)
All outcomes
High risk 30% (85 out of 285) of all randomised par-
ticipants did not complete the trial; 28 of
these were admitted to hospital during ini-
tial ED presentation, after they had been
randomised. Outcomes are unknown. A
further 19% (dexamethasone group) and
25% (prednisolone group) were lost to fol-
low-up, so again, outcomes are unknown
Selective reporting (reporting bias) Low risk All stated outcomes reported numerically
or narratively but unclear whether trial was
prospectively registered
Other bias Low risk None noted
Langton Hewer 1998
Methods Design: randomised (stratified by age and gender), double-blind trial
Duration: corticosteroid treatment continued while participants admitted, then for a
maximum of 3 days post discharge depending on symptoms. Follow-up continued until
2 weeks after discharge
Setting: treatment initiated on an inpatient basis and completed at home; trial carried
out in UK
Participants Population:98 childrenwith an acute exacerbationof asthmawere randomised to receive
a high dose (n = 30), medium dose (n = 33) or low dose (n = 35) of prednisolone
Age: 1-15 years; mean age (SE) in the high-dose group was 5.00 (0.71) years, in the
medium-dose group 5.64 (0.60) years and in the low-dose group 5.39 (0.61) years
Inclusion criteria: aged 1-15 with diagnosis of acute asthma requiring admission
Exclusion criteria: already receiving oral corticosteroids or prescribed oral corticosteroids
within previous 14 days, significant underlying cardiac or pulmonary disease, unavailable
investigating team, required IV therapy at the time of admission. Children could be
enrolled only once. Children were withdrawn if they required IV therapy, failed to
respond adequately to nebulisers or had oxygen saturation persistently < 91% in air or
had response to therapy that was considered too slow
Percentage withdrawn: withdrawal from high-dose group was 20%, from medium-
dose group 9.1% and from low-dose group 5.7%
Allowedmedication: following standard hospital asthma protocols (e.g. nebulised salbu-
tamol 0.5-4 hourly according to need)
Disallowed medication: oral corticosteroids within 14 days of admission
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Interventions Prednisolone high-dose group: 2 mg/kg prednisolone once daily while an inpatient
and up to 3 days post discharge (maximum daily dose 60 mg; total dose for 20 kg child
receiving 5-day course 200 mg prednisolone equivalent)
Predisolone medium-dose group: 1 mg/kg prednisolone once daily while an inpatient
and up to 3 days post discharge (maximum daily dose 60 mg; total dose for 20 kg child
receiving 5-day course 100 mg prednisolone equivalent)
Prednisolone low-dose group: 0.5 mg/kg prednisolone once daily while an inpatient
and up to 3 days post discharge (maximum daily dose 60 mg; total dose for 20 kg child
receiving 5-day course 50 mg prednisolone equivalent)
Outcomes Asthma severity score while an inpatient (comprising clinical asthma score (based on
respiratory effort, auscultation findings and patient distress, eachmeasured on a 0-6 scale,
giving a maximum score of 18; the higher the score, the worse the symptoms), oxygen
saturations, pulse rate and, when possible, FEV1 and PEFR), duration of admission,
number of nebulisers given. Once home, participants/parents were asked to complete
asthmadiaries for 2weeks includingnight-time symptoms, SABAuse and,whenpossible,
morning and evening PEFR and cough and wheeze score
Notes Type of publication: peer-reviewed
Funding: trial authors supported by the Royal Alexander Rockinghorse Appeal
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomisation had been previously per-
formed by the hospital pharmacist..” “strat-
ification of randomisation was undertaken.
.”
Allocation concealment (selection bias) Low risk Randomisation had been previously per-
formed by the hospital pharmacist, who
used sealed envelopes disclosing the re-
quired dose
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Dose of prednisolone was prepared on a
different hospital ward and was unknown
to investigating team and ward staff where
the child had been admitted
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Code for dosages of prednisolone given to
each patient was broken only once; all pa-
tients had been discharged from the hospi-
tal and their 2-week follow-up completed
Incomplete outcome data (attrition bias)
All outcomes
High risk Unbalanced attrition in the intervention
groups; < 10% in medium- and low-dose
groups and 20% in higher-dose group; 3 (1
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from each group) were considered to be re-
sponding too slowly to treatment, so were
switched to standard hospital protocol; 5
received IV therapy (2 from 2 mg group, 2
from1mg group and 1 from0.5mg group)
; 1 had already received oral steroids from
GP (1mggroup); 3 additional participants,
all from 2 mg group, withdrew because of
vomiting, diagnosis of pneumonia or par-
ent withdrawal of consent
Selective reporting (reporting bias) Low risk All stated outcomes reported, although un-
clear whether trial was prospectively regis-
tered
Other bias Low risk None noted
Lederle 1987
Methods Design: randomised, double-blind trial
Duration: corticosteroid treatment continued for 7 weeks post discharge; follow-up
continued until 12 weeks after initial admission
Setting: treatment initiated while inpatient and completed at home
Participants Population: 43 adults with an acute exacerbation of asthma were randomised to a long
taper course (n = 22) or a short taper course (n = 21) of prednisolone
Age: 30-78 years; mean age in long taper group 62.6 years and in short taper group 63
years
Inclusion criteria: men admitted to medicine services with exacerbation of asthma
requiring systemic steroids; exacerbation defined as worsening dyspnoea due to airways
obstruction with no other cause identified, and evidence of a reversible component to
obstruction
Exclusion criteria: already receiving oral corticosteroids; evidence of pneumonia, pul-
monary oedema or cardiomegaly on chest x-ray; other significant lung disease such as
bronchiectasis, fibrosis, cancer; renal failure, hepatic failure and inability to comply with
study protocol
Percentage withdrawn: withdrawal 0% in both treatment arms
Allowed medication: beta-agonists and theophylline allowed at treating physician’s dis-
cretion. Inhaled beclomethasone given throughout study period
Disallowed medication: antibiotics not allowed once tapering period had begun
Interventions Prednisolone long taper group: 45 mg prednisolone once daily reducing by 5 mg
weekly to 0 mg daily over 7 weeks (total dose 1575 mg prednisolone equivalent)
Prednisolone short taper group: 45 mg prednisolone once daily reducing by 5 mg daily
to 0 mg daily over 7 days (total dose 225 mg prednisolone equivalent)
Outcomes Failure of tapering regimen (defined as re-exacerbation of asthma requiring further cor-
ticosteroid administration during 12-week follow-up period); symptom diary with 10-
point VAS to evaluate breathing each day from ’best’ to ’worst’; physical examination,
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spirometry, symptoms, adverse events and compliance assessed at 4, 8 and 12 weeks post
admission
Notes Type of publication: peer-reviewed
Funding: placebo tablets provided by Rowell Laboratories Inc., Baudette, Minn
Other:mean age in both groups over 60, all but 5 included participants with > 10 pack-
year smoking history, mean of 49 years of age in long-taper group and 56 in short-taper
group. Baseline spirometry results also suggest that many participants may have had a
diagnosis of COPD (mean FEV1 /FVC in both groups < 0.7). Study authors acknowledge
that many participants may have had COPD with a reversible component
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Patients were randomly assigned..”; no
further details
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk All participants received identical calender
blister packs that contained the tapering
regimen
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Primary outcome of failure of tapering
regimen (i.e. re-exacerbation requiring ad-
ditional oral steroids) decision made by
physician blinded to participant allocation,
as was decision to admit
Incomplete outcome data (attrition bias)
All outcomes
Low risk All 43 enrolled and randomised partici-
pants followed up to 12 weeks as planned
(2 withdrew before starting taper; results
not included)
Selective reporting (reporting bias) High risk Not all outcomes reported in a way allow-
ing for meta-analysis. FEV1 outcome re-
ported as percentage of baseline value with-
out variance. Diary measures narratively
reported in text with minimal supporting
data
Other bias Low risk None noted
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Methods Design: randomised, double-blind trial
Duration: randomised corticosteroid treatment continued for first 48 hours of admis-
sion; all participants still admitted after 48 hours switched to standard hospital protocol
dose of steroids until discharge. Participants continued standard steroid treatment for a
total of 5-10 days at the discretion of the treating physician. Follow-up continued until
7-14 days after discharge
Setting: treatment initiated in the ED with a loading dose of prednisolone and ran-
domised treatment continued on inpatient basis for up to 48 hours; trial carried out in
USA
Participants Population: 152 children with an acute exacerbation of asthma were randomised to a
high-dose (n = 74) or a low-dose (n = 78) course of prednisolone
Age: 2-18 years; mean age (SD) in the high-dose group was 7.9 (4.4) years and in the
low-dose group 7.0 (3.8) years
Inclusion criteria: aged 2-18 years with physician-diagnosed asthma and ≥ 2 previous
visits to ED or primary care provider for asthma care, at which time a beta-2-agonist was
prescribed for acute symptoms; treated in the ED with a standardised asthma protocol
based on NAEPP Guidelines. After initial therapy, participants were assessed by an
attending physician; those determined to require admission to the hospital were eligible
for enrolment
Exclusion criteria: clinical decision to begin continuous intravenous beta-agonist in-
fusion; clinical decision to begin intravenous methylprednisolone therapy; clinical de-
cision to admit to the Pediatric Intensive Care Unit; other concurrent disease such as
sickle cell disease, cystic fibrosis or cardiac disease; any contraindication to corticosteroid
administration; any systemic corticosteroid treatment within 2 weeks of presentation to
the ED; potential participants excluded if informed consent not obtained
Percentage withdrawn: withdrawal 0% in both treatment arms
Allowedmedication: albuterol on an inpatient basis. Study participants were allowed to
continue other medications previously prescribed, including antihistamines, leukotriene
inhibitors and inhaled corticosteroids. Both groups received a loading dose of pred-
nisolone (2 mg/kg up to maximum 60 mg) in the ED followed by randomised treatment
Disallowed medication: intravenous beta-2-agonist or corticosteroid, systemic corti-
costeroid within 2 weeks of presentation to the ED
Interventions Prednisolone high-dose group: 4 mg/kg/d (1 mg/kg qds) for 48 hours, then 2 mg/kg/
d (1 mg/kg bd) until discharge (maximum 30 mg per dose; total dose for 20 kg child
receiving 5-day course 400 mg prednisolone equivalent)
Prednisolone low-dose group: 2 mg/kg/d (1 mg/kg bd) for≥ 48 hours and continuing
duration of hospital admission (maximum 30 mg per dose; total dose for 20 kg child
receiving 5-day course 200 mg prednisolone equivalent)
Outcomes Time measured from administration of loading dose of prednisolone in the ED until
home dose of albuterol administered; time measured from writing of the admission
order until writing of the discharge order; time spent at each severity level of the asthma
care pathway; rate and degree of change in FEV1 and PEFR between treatment groups;
differences in clinical asthma symptom scores during hospitalisation between treatment
groups; rate of relapse between treatment groups
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Notes Type of publication: trial registration only on www.clinicaltrials.gov; unpublished data
provided by trial author
Funding: Children’s Hospital of Philadelphia
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk After informed consent was obtained, par-
ticipants were randomised by the pharmacy
in blocks of 6 and were stratified by severity
level in the asthma pathway
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind; “2mg/kg/day orally divided
12 hourly (maximum30mg/dose) alternat-
ing with placebo”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Described as double-blind (“Subject, Care-
giver, Investigator, Outcomes Assessor”)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low drop-out overall; 16 (10.5%) partici-
pants withdrawn from study (13.5% from
high-dose arm and 7.7% from low-dose
arm) and 145/152 (95.4%) participants
followed up by phone
Selective reporting (reporting bias) Unclear risk Paper has not yet been published. Some re-
sults are posted on clinicaltrials.gov; study
authors kindly provided us with an unpub-
lishedmanuscript. Some listed outcomes as
yet are not fully reported (peak flow, clini-
cal asthma score)
Other bias Low risk None noted
O’Driscoll 1993
Methods Design: randomised, double-blind trial
Duration: corticosteroid treatment continued for 10-17 days depending on allocation;
follow-up continued until 4-6 weeks after discharge
Setting: treatment initiated on inpatient basis and completed at home; trial carried out
in the UK
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Participants Population: 39 adults with an acute exacerbation of asthma were randomised to a
tapering (n = 18 completed) or non-tapering (n = 17 completed) course of prednisolone
Age: 16-55 years; mean age (range) in tapering group was 28 (18-55) years and in non-
tapering group 37 (20-53) years
Inclusion criteria: 16-55 years of age presenting with an acute asthma attack with PEFR
< 65% predicted, admission under care of designated chest physician, ability to give
informed consent and maintain PEFR diary for 28 days, use of inhaled corticosteroid
(400-2000 mcg daily) on discharge
Exclusion criteria: major medical illnesses (especially pneumonia, heart failure,
bronchiectasis and lung cancer), COPD, long-term use of oral steroids, nebulisation at
home, unable to comply with trial protocol, receiving IV hydrocortisone for > 2 days,
requiring mechanical ventilation, had taken part in the trial during preceding 2 months
Percentage withdrawn: 4 participants (10.3%) withdrawn overall but number from
each group not reported
Allowedmedication: all other asthma treatments allowed at the discretion of the partici-
pant’s personal physician, provided theywere allowed under trial criteria. All participants
received short-acting beta-2-agonists and inhaled corticosteroids
Disallowed medication: not reported
Interventions Prednisolone taper group: 40 mg prednisolone once daily for 10 days, then tapering
by 5 mg/d for 7 days (total dose 540 mg prednisolone equivalent)
Prednisolone non-taper group: 40 mg prednisolone once daily for 10 days, followed
by placebo taper (total dose 400 mg prednisolone equivalent)
Outcomes PEFR, asthma symptoms on a numerical scale (1-5)
Notes Type of publication: peer-reviewed
Funding: placebo tablets provided by Pfizer UK Ltd
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Prescriptions were sealed in a plain brown
envelope and shuffled into a random order
Allocation concealment (selection bias) Low risk Prescriptions were sealed in a plain brown
envelope and shuffled into a random order.
. whenever an eligible patient entered the
trial, one of the investigators would open
the next envelope anddispatch the enclosed
coded prescription to the pharmacy
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants received oral prednisolone for
the active tapering arm or identical placebo
tablets
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O’Driscoll 1993 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Only the pharmacist was unblinded to al-
location and prepared study medications
according to the coded prescription; how-
ever, it is not clear whether outcome assess-
ments were performed blinded throughout
the trial
Incomplete outcome data (attrition bias)
All outcomes
Low risk Only 4 of 39 participants were enrolled and
randomised but did not complete the trial.
Twowere lost to follow-up and2werewith-
drawn for protocol violation and incorrect
enrolment (PEFR did not meet inclusion
criteria)
Selective reporting (reporting bias) High risk Many diary outcomes are not reported nu-
merically so cannot be included in the
meta-analysis. Data displayed graphically
in many cases with no variance. Not clear
whether study was prospectively registered
Other bias Low risk None noted
Qureshi 2001
Methods Design: randomised, open-label trial
Duration: corticosteroid treatment continued for 2-5 days depending on allocation;
follow-up continued until 11-14 days after ED discharge
Setting: treatment initiated in the ED and completed at home; trial carried out in the
USA
Participants Population: 628 children with an acute exacerbation of asthma were randomised to
receive prednisolone (n = 319) or dexamethasone (n = 309)
Age: 2-18 years; median age (95% CIs) in prednisolone group 6 (6-7) years and in
dexamethasone group 6 (5-7) years
Inclusion criteria: 2-18 years old with known history of asthma (≥ 2 episodes of wheez-
ing treated with β-adrenergic agonists with or without steroids) and presenting to pae-
diatric ED with an acute exacerbation, defined as worsening of asthmatic symptoms or
increased difficulty in breathing with worsening of peak expiratory flow rates. Children
were considered for the study if they required ≥ 2 albuterol nebuliser treatments in the
ED
Exclusion criteria: reported use of oral corticosteroids in the 4 weeks before the current
episode, history of intubation, varicella exposure in preceding3weeks, concurrent stridor,
possible presence of an intrathoracic foreign body, chronic respiratory disease (e.g. cystic
fibrosis), cardiac disease, need for immediate airway intervention
Percentage withdrawn: withdrawal from the prednisolone group was 18.2% and from
the dexamethasone group was 12%
Allowed medication: All children were treated according to the standard ED asthma
treatment protocol (nebulised albuterol and ipratropium according to asthma severity)
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. Albuterol inhalations were recommended on a 4- to 6-hour basis for the first 2 days
after discharge, then as needed
Disallowed medication: No other asthma medications were to be used during the next
10 days, apart from those detailed above
Interventions Prednisolone group: 2 mg/kg prednisolone initial dose, then 1 mg/kg daily for 5 days
(maximum daily dose 60 mg; total dose for 20 kg child 120 mg prednisolone equivalent)
Dexamethasone group: 0.6 mg/kg once daily for 2 days (maximum daily dose 16 mg;
total dose for 20 kg child 160 mg prednisolone equivalent)
Outcomes Rate of relapse (defined as an unscheduled visit to a medical facility resulting from par-
ticipant’s or parent’s perception of persistent, worsening or recurrent asthma symptoms
in the 10 days after discharge from the ED), rate of hospitalisation (initially from the ED
and after relapse), frequency of vomiting, reported medication compliance, persistence
of symptoms, school days or workdays missed
Notes Type of publication: peer-reviewed
Funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quasi-randomised trial; children allocated
to treatment group depending on the day
on which they attended the ED (odd days
prednisolone, even days dexamethasone)
Allocation concealment (selection bias) High risk Allocation unconcealed because of the na-
ture of sequence generation
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label trial
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Open-label trial; however, primary out-
come (decision to seek medical care for
deteriorating symptoms) made indepen-
dently of study investigators
Incomplete outcome data (attrition bias)
All outcomes
Low risk Balanced drop-out. However, significantly
more children excluded from prednisolone
groupbecause of vomiting of studymedica-
tion. Intention-to-treat analysis performed
for primary outcome, assuming that all
children excluded because of vomiting and
those lost to follow-up had a relapse; re-
sult favoured dexamethasone but not sig-
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nificantly
Selective reporting (reporting bias) Low risk All outcomes reported numerically, al-
though unclear whether trial was prospec-
tively registered
Other bias Low risk None noted
Viska 2008
Methods Design: randomised trial; blinding not described
Duration: corticosteroid treatment continued for 2 weeks with follow-up continuing
until 6 weeks
Setting: treatment with initiated ’in hospital’ and completed at home; trial carried out
in Indonesia
Participants Population: 86 adults with an acute exacerbation of asthma were randomised to a high-
dose or low-dose course of prednisolone (n for each group not given)
Age: adults; age range not given
Inclusion criteria: adults with acute exacerbation of asthma presenting to hospital
Exclusion criteria: not reported
Percentage withdrawn: 76 out of 86 participants were ’eligible to be included until the
end of the study’; 11.6% were withdrawn overall
Allowed medication: not reported
Disallowed medication: not reported
Interventions Prednisolone high-dose group: 36 mg prednisolone once daily for 2 weeks (total dose
504 mg prednisolone equivalent)
Prednisolone low-dose group: 12 mg prednisolone once daily for 2 weeks (total dose
168 mg prednisolone equivalent)
Outcomes Relapse (unscheduled visit to healthcare provider), peak flow, asthma control test
Notes Type of publication: conference abstract; study authors contacted for further informa-
tion on 21 September 2015; at time of publication, no response received
Funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Enrolled and randomly divided”; no fur-
ther details
Allocation concealment (selection bias) Unclear risk No details
65Different oral corticosteroid regimens for acute asthma (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Viska 2008 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding not described, so assume open-
label trial
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Blinding not described, so assume open-
label trial
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 86 participants enrolled; 76 completed the
trial. Not clear which treatment arms they
dropped out of as total n for each group
not given
Selective reporting (reporting bias) High risk Conference abstract, so study details min-
imal and not clear if prospectively regis-
tered. Unable to extract data for inclusion
in review, as number randomised to each
treatment arm not provided
Other bias Low risk None noted
ACTH = adrenocorticotropic hormone
CI = confidence interval
COPD = chronic obstructive pulmonary disease
ED = emergency department
FEV1 = forced expiratory volume in 1 second
FVC = forced vital capacity
HCP = healthcare provider
ICS = inhaled corticosteroid
ICU = intensive care unit
IQR = interquartile range
ITT = intention-to-treat
IV = intravenous
MDI = metered dose inhaler
NAEPP = National Asthma Education and Prevention Program
PACQLQ = Paediatric Asthma Caregiver’s Quality of Life Questionnaire
PEF = peak expiratory flow
PEFR = peak expiratory flow rate
PIS = pulmonary index score
PRAM = paediatric respiratory assessment measure
PSAS = patient self assessment sheet
SABA = short-acting beta-agonist
SaO2 = oxygen saturated as measured by blood analysis
SD = standard deviation
VAS = visual analogue scale
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Andrews 2014 Review article
Bowler 1990 Different IV regimens part of randomised treatment
Bowler 1992 Different IV regimens part of randomised treatment
Brand 2000 Comparison of prednisolone solution vs crushed tablets
Brand 2001 Not a randomised controlled trial
Britton 1976 Different intravenous steroid regimens part of randomised treatment
Castilla Barrios 1994 Comparison of intravenous steroids
Chanez 1996 Cross-over trial; comparison of different steroids for long-term use
Chapela 1995 Comparison of equivalent dose and duration of deflazacort and prednisolone
Dahlen 2007 Mixed population of participants with asthma and COPD; comparison with placebo
Dawson 1993 Comparison of prednisolone solution vs crushed tablets
Dente 2006 Comparison of oral steroids vs placebo; not in acute asthma
Ebrahimi 2007 Comparison of intravenous steroids
Figueira 1996 Comparison of intravenous steroids
Gartner 2004 Comparison of equivalent dose and duration of deflazacort and prednisolone
Gonzalez 1994 Wrong population and wrong comparator; children with acute wheezy bronchitis
Guerot 1971 Trial of inhaled, not oral, steroids
Hasegawa 1998 Not a randomised controlled trial
Hatton 1995 Comparison of oral steroids vs placebo
Ho 1994 Single-dose oral steroids vs placebo
Innes 2002 Comparison of US and UK guidelines for management of asthma exacerbations. Different doses of oral
steroids not the only variable
Kato 2004 Trial of theophylline in addition to systemic steroids for acute asthma
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Lucas-Bouwman 2001 Comparison of prednisolone solution vs crushed tablets
Marquette 1995 Comparison of intravenous steroids
Mathew 2015 Not a randomised controlled trial
Matsumoto 1994 Not a randomised controlled trial
Micheletto 1997 Not acute asthma; comparison of equivalent doses of prednisolone and deflazacort
Middelveld 2009 Mixed population of participants with asthma and COPD; placebo-controlled
Pierson 1971 Trial of aminophylline in status asthmaticus
Pierson 1974 Trial of intravenous steroids
Schwarz 2015 Not a randomised controlled trial; review article
Silva 2007 Acute wheezing rather than asthma, oral steroids vs nebulised steroids and placebo
Silva 2008 Acute wheezing rather than asthma, oral steroids vs nebulised steroids and placebo
Skinner 1993 Not an RCT; commentary on O’Driscoll 1993
Webb 1986 3-way cross-over study
COPD = chronic obstructive pulmonary disease
IV = intravenous
RCT = randomised controlled trial
Characteristics of studies awaiting assessment [ordered by study ID]
Tanifuji 2001
Methods Unclear
Participants 33 participants with asthma with PEF 40-60% of best/predicted value, requiring hospitalisation
Interventions High-dose (120 mg/d) vs low-dose (60 mg/d) prednisolone
Outcomes Number of days taken to reach 70-80% of best/predicted PEF, duration of hospitalisation, adverse events, recurrence
of asthma symptoms 1 month post discharge
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Notes Published as abstract only. Study authors contacted by post on 14 July 2015 to clarify trial design and route of steroid
administration and to assess whether study meets inclusion criteria. At time of publication, no response received
Characteristics of ongoing studies [ordered by study ID]
NCT01241006
Trial name or title Single oral dose of dexamethasone vs 5 days of prednisone in adult asthma
Methods Parallel, randomised, double-blind trial
Participants Adults with mild to moderate asthma exacerbations
Interventions Single dose of oral dexamethasone 12 mg vs oral prednisone 60 mg/d for 5 days
Outcomes Primary outcome: relapse for worsening asthma within 14 days of emergency department visit
Secondary outcomes: compliance, side effects, symptoms (including rescue inhaler use, wheezing, cough,
shortness of breath and difficulty with activities of daily living)
Starting date January 2011
Contact information Matthew Rehrer
Alameda County Medical Center
Oakland
California
United States
94602
matthewrehrer@gmail.com
Notes Estimated trial completion date May 2015; no study results available at this time
NCT02192827
Trial name or title Use of dexamethasone in paediatric asthma exacerbations
Methods Parallel, randomised, open-label trial
Participants Participants aged 2-20 years presenting to the emergency department (ED) with a mild to moderate exacer-
bation of asthma
Interventions Single-dose 0.6 mg/kg of dexamethasone given in the ED vs 2 doses of 0.6 mg/kg of dexamethasone; first
dose given in ED and second at home
Outcomes Primary outcome: peak flow at 5 days
Secondary outcomes: relapse requiring medical attention, side effects (including vomiting, mood swings,
behaviour changes, appetite changes, sweating or headache)
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Starting date April 2015
Contact information Meghan E. Martin
Women and Children’s Hospital of Buffalo
Buffalo
New York
United States,
14222
MegMartinMD@hotmaill.com
Notes Estimated trial completion date April 2017
NCT02725008
Trial name or title Trial of 1 vs 2 doses of dexamethasone for paediatric asthma exacerbation (R2D2)
Methods Paralell, randomised, double-blind
Participants Males and females aged 18 months-20 years with a history of asthma defined as ≥ 2 prior episodes of
respiratory illness characterised by wheezing treated with inhaled beta-agonists. Estimated enrolment 220
participants
Interventions 1 dose of oral dexamethasone 0.6 mg/kg (maximum dose 16 mg) in the ED and a second dose to take 24
hours after ED visit vs 1 dose in the ED plus a placebo dose 24 hours after ED visit
Outcomes Primary outcomes: treatment failure; number of participants who experienced any of the following outcomes
- unplanned hospital admission for asthma symptoms, unplanned ED visit for asthma symptoms, unplanned
urgent care visit for asthma symptoms, unplanned primary care physician visit for asthma symptoms, pre-
scription of a course of steroids
Secondary outcome: patient self assessment score (PSAS)
Starting date July 2015
Contact information Geoffrey W. Jara-Almonte, MD
New York Methodist Hospital
Brooklyn, New York
United States
11215
gjaraalmonte@gmail.com
Notes Estimated trial completion date July 2017
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D A T A A N D A N A L Y S E S
Comparison 1. Adults: higher dose/longer course vs lower dose/shorter course
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Re-admission during follow-up
period
4 Odds Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Longer vs shorter course
prednisolone
4 142 Odds Ratio (M-H, Random, 95% CI) 1.35 [0.38, 4.79]
2 Asthma symptoms: asthma
severity score
1 Mean Difference (IV, Random, 95% CI) Totals not selected
2.1 Longer vs shorter course
prednisolone
1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Asthma symptoms: complete
resolution
1 Odds Ratio (M-H, Random, 95% CI) Totals not selected
3.1 Longer vs shorter course
prednisolone
1 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4 New exacerbation during
follow-up period: requiring
visit to healthcare provider
4 Risk Difference (M-H, Random, 95% CI) Subtotals only
4.1 Longer vs shorter course
prednisolone
2 55 Risk Difference (M-H, Random, 95% CI) -0.00 [-0.14, 0.14]
4.2 Stable vs tapered
prednisolone
2 41 Risk Difference (M-H, Random, 95% CI) 0.09 [-0.07, 0.26]
5 New exacerbation during
follow-up period: oral
corticosteroids prescribed
3 122 Odds Ratio (M-H, Random, 95% CI) 0.62 [0.23, 1.68]
5.1 Longer vs shorter course
prednisolone
3 122 Odds Ratio (M-H, Random, 95% CI) 0.62 [0.23, 1.68]
6 Lung function tests: trough
PEFR
2 Mean Difference (IV, Random, 95% CI) Subtotals only
6.1 Longer vs shorter
prednisolone (trough PEFR)
2 79 Mean Difference (IV, Random, 95% CI) -4.81 [-45.82, 36.
20]
7 Lung function tests: FEV1%
predicted
2 Mean Difference (IV, Random, 95% CI) Subtotals only
7.1 Stable vs tapered
prednisolone (FEV1%
predicted)
2 41 Mean Difference (IV, Random, 95% CI) -1.02 [-4.62, 2.58]
8 Lung function tests: number of
participants achieving personal
best at 4 weeks
1 Odds Ratio (M-H, Random, 95% CI) Totals not selected
8.1 Longer vs shorter course
prednisolone
1 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9 All adverse events 1 Odds Ratio (M-H, Random, 95% CI) Totals not selected
9.1 Longer vs shorter course
prednisolone
1 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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Comparison 2. Adults: prednisolone vs dexamethasone
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Re-admission during follow-up
period
1 Odds Ratio (M-H, Random, 95% CI) Totals not selected
2 Asthma symptoms: returned to
normal activities within 3 days
1 191 Odds Ratio (M-H, Random, 95% CI) 0.44 [0.19, 1.01]
3 New exacerbation during
follow-up period: any ED visit
after discharge
1 Odds Ratio (M-H, Random, 95% CI) Totals not selected
4 New exacerbation during
follow-up period: unscheduled
visit to primary healthcare
provider
1 Odds Ratio (M-H, Random, 95% CI) Totals not selected
Comparison 3. Children: higher dose/longer course vs lower dose/shorter course
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Admission at initial presentation 1 Odds Ratio (M-H, Random, 95% CI) Totals not selected
1.1 Longer vs shorter course
dexamethasone
1 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2 Re-admission during follow-up
period
5 Odds Ratio (M-H, Random, 95% CI) Totals not selected
2.1 Higher-dose vs lower-dose
prednisolone
3 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 Longer vs shorter course
prednisolone
1 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.3 Longer vs shorter course
dexamethasone
1 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3 Asthma symptoms: clinical
asthma score at discharge
1 Mean Difference (IV, Random, 95% CI) Totals not selected
3.1 High vs medium dose 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.2 High vs low dose 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.3 Medium vs low dose 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 Asthma symptoms: symptom
free by 7 days
1 201 Odds Ratio (M-H, Random, 95% CI) 1.22 [0.67, 2.19]
4.1 Longer vs shorter course
prednisolone
1 201 Odds Ratio (M-H, Random, 95% CI) 1.22 [0.67, 2.19]
5 Serious adverse events 1 201 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5.1 Longer vs shorter course
prednisolone
1 201 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6 New exacerbation during
follow-up period: oral
corticosteroids prescribed
4 Odds Ratio (M-H, Random, 95% CI) Subtotals only
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6.1 Higher-dose vs lower-dose
prednisolone
2 231 Odds Ratio (M-H, Random, 95% CI) 1.38 [0.25, 7.47]
6.2 Longer vs shorter course
prednisolone
1 201 Odds Ratio (M-H, Random, 95% CI) 0.61 [0.19, 1.94]
6.3 Longer vs shorter course
dexamethasone
1 100 Odds Ratio (M-H, Random, 95% CI) 0.24 [0.05, 1.19]
7 New exacerbation during
follow-up period: unscheduled
visit to healthcare provider
1 Odds Ratio (M-H, Random, 95% CI) Totals not selected
7.1 Longer vs shorter course
dexamethasone
1 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8 Lung function tests: FEV1%
predicted at discharge
1 Mean Difference (IV, Random, 95% CI) Totals not selected
8.1 High vs medium dose 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8.2 High vs low dose 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8.3 Medium vs low dose 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9 Lung function tests: PEFR%
predicted at discharge
1 Mean Difference (IV, Random, 95% CI) Totals not selected
9.1 High vs medium dose 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9.2 High vs low dose 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9.3 Medium vs low dose 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10 All adverse events: longer vs
short course prednisolone
1 201 Odds Ratio (M-H, Random, 95% CI) 0.67 [0.11, 4.08]
11 All adverse events: higher-dose
vs lower-dose prednisolone
3 Odds Ratio (M-H, Random, 95% CI) Subtotals only
11.1 Facial fullness 2 231 Odds Ratio (M-H, Random, 95% CI) 1.28 [0.58, 2.80]
11.2 Facial erythema 2 231 Odds Ratio (M-H, Random, 95% CI) 0.83 [0.33, 2.06]
11.3 Change in appetite 2 231 Odds Ratio (M-H, Random, 95% CI) 0.92 [0.49, 1.72]
11.4 Abdominal pain 2 231 Odds Ratio (M-H, Random, 95% CI) 1.36 [0.57, 3.25]
11.5 Diarrhoea 2 231 Odds Ratio (M-H, Random, 95% CI) 2.43 [0.43, 13.84]
11.6 Anxiety 2 231 Odds Ratio (M-H, Random, 95% CI) 1.75 [0.20, 15.49]
11.7 Euphoria 2 231 Odds Ratio (M-H, Random, 95% CI) 0.79 [0.30, 2.10]
11.8 Depression 2 232 Odds Ratio (M-H, Random, 95% CI) 0.54 [0.16, 1.79]
11.9 Quiet and reserved 2 231 Odds Ratio (M-H, Random, 95% CI) 1.73 [0.69, 4.36]
11.10 Hyperactive 3 318 Odds Ratio (M-H, Random, 95% CI) 0.89 [0.31, 2.52]
11.11 Aggressive behaviour 2 231 Odds Ratio (M-H, Random, 95% CI) 2.06 [0.02, 267.49]
Comparison 4. Children: prednisolone vs dexamethasone
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Admission at initial presentation 3 1007 Odds Ratio (M-H, Random, 95% CI) 1.08 [0.74, 1.58]
2 Re-admission during follow-up
period
3 985 Odds Ratio (M-H, Random, 95% CI) 0.44 [0.15, 1.33]
3 Asthma symptoms: PIS 1 110 Mean Difference (IV, Random, 95% CI) -0.10 [-0.45, 0.25]
4 Asthma symptoms: PSAS 1 110 Mean Difference (IV, Random, 95% CI) 0.01 [-0.67, 0.69]
5 Asthma symptoms: PRAM 1 218 Mean Difference (IV, Random, 95% CI) 0.0 [-0.36, 0.36]
6 Asthma symptoms 1 Odds Ratio (M-H, Random, 95% CI) Totals not selected
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6.1 Persistent cough 1 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6.2 Wheeze 1 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6.3 Tightness of chest 1 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6.4 Night wakening 1 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6.5 Difficulty maintaining
normal activities
1 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7 Serious adverse events 2 255 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8 New exacerbation during
follow-up period: unscheduled
visit to healthcare provider
4 981 Odds Ratio (M-H, Random, 95% CI) 0.85 [0.54, 1.34]
9 New exacerbation during
follow-up period: oral
corticosteroids prescribed
1 242 Odds Ratio (M-H, Random, 95% CI) 0.29 [0.10, 0.81]
10 Adverse event: vomiting 3 867 Odds Ratio (M-H, Random, 95% CI) 3.05 [0.88, 10.55]
Analysis 1.1. Comparison 1 Adults: higher dose/longer course vs lower dose/shorter course, Outcome 1 Re-
admission during follow-up period.
Review: Different oral corticosteroid regimens for acute asthma
Comparison: 1 Adults: higher dose/longer course vs lower dose/shorter course
Outcome: 1 Re-admission during follow-up period
Study or subgroup Longer course Shorter course Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Longer vs shorter course prednisolone
Hasegawa 2000 0/10 0/10 Not estimable
Jones 2002 1/24 0/20 15.1 % 2.62 [ 0.10, 67.83 ]
Lederle 1987 6/22 5/21 84.9 % 1.20 [ 0.30, 4.74 ]
O Driscoll 1993 0/18 0/17 Not estimable
Subtotal (95% CI) 74 68 100.0 % 1.35 [ 0.38, 4.79 ]
Total events: 7 (Longer course), 5 (Shorter course)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.19, df = 1 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 0.46 (P = 0.64)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours longer Favours shorter
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Analysis 1.2. Comparison 1 Adults: higher dose/longer course vs lower dose/shorter course, Outcome 2
Asthma symptoms: asthma severity score.
Review: Different oral corticosteroid regimens for acute asthma
Comparison: 1 Adults: higher dose/longer course vs lower dose/shorter course
Outcome: 2 Asthma symptoms: asthma severity score
Study or subgroup Longer course Shorter course
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Longer vs shorter course prednisolone
Jones 2002 (1) 24 1.9 (0.8) 20 2.6 (1.1) -0.70 [ -1.28, -0.12 ]
-4 -2 0 2 4
Favours longer Favours shorter
(1) Mean of individuals’ mean overall severity (1-7; 1=no symptoms, 7=worst symptoms) days 6-21 (i.e. during randomised treatment)
Analysis 1.3. Comparison 1 Adults: higher dose/longer course vs lower dose/shorter course, Outcome 3
Asthma symptoms: complete resolution.
Review: Different oral corticosteroid regimens for acute asthma
Comparison: 1 Adults: higher dose/longer course vs lower dose/shorter course
Outcome: 3 Asthma symptoms: complete resolution
Study or subgroup Longer course Shorter course Odds Ratio Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Longer vs shorter course prednisolone
O Driscoll 1993 (1) 5/18 7/17 0.55 [ 0.13, 2.26 ]
0.01 0.1 1 10 100
Favours longer Favours shorter
(1) Complete resolution by day 28
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Analysis 1.4. Comparison 1 Adults: higher dose/longer course vs lower dose/shorter course, Outcome 4
New exacerbation during follow-up period: requiring visit to healthcare provider.
Review: Different oral corticosteroid regimens for acute asthma
Comparison: 1 Adults: higher dose/longer course vs lower dose/shorter course
Outcome: 4 New exacerbation during follow-up period: requiring visit to healthcare provider
Study or subgroup Higher/longer Lower/shorter
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Longer vs shorter course prednisolone
Hasegawa 2000 2/10 2/10 16.2 % 0.0 [ -0.35, 0.35 ]
O Driscoll 1993 1/18 1/17 83.8 % 0.00 [ -0.16, 0.15 ]
Subtotal (95% CI) 28 27 100.0 % 0.00 [ -0.14, 0.14 ]
Total events: 3 (Higher/longer), 3 (Lower/shorter)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.04 (P = 0.97)
2 Stable vs tapered prednisolone
Cydulka 1998 (1) 1/7 0/8 27.2 % 0.14 [ -0.17, 0.45 ]
Karan 2002 1/13 0/13 72.8 % 0.08 [ -0.11, 0.27 ]
Subtotal (95% CI) 20 21 100.0 % 0.09 [ -0.07, 0.26 ]
Total events: 2 (Higher/longer), 0 (Lower/shorter)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.13, df = 1 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 1.15 (P = 0.25)
Test for subgroup differences: Chi2 = 0.80, df = 1 (P = 0.37), I2 =0.0%
-0.5 -0.25 0 0.25 0.5
Favours higher/longer Favours lower/shorter
(1) Wheezing or dyspnoea requiring the patient to seek medical attention within 21 days of the initial visit”
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Analysis 1.5. Comparison 1 Adults: higher dose/longer course vs lower dose/shorter course, Outcome 5
New exacerbation during follow-up period: oral corticosteroids prescribed.
Review: Different oral corticosteroid regimens for acute asthma
Comparison: 1 Adults: higher dose/longer course vs lower dose/shorter course
Outcome: 5 New exacerbation during follow-up period: oral corticosteroids prescribed
Study or subgroup Longer course Shorter course Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Longer vs shorter course prednisolone
Jones 2002 2/24 2/20 23.2 % 0.82 [ 0.10, 6.40 ]
Lederle 1987 9/22 11/21 67.5 % 0.63 [ 0.19, 2.10 ]
O Driscoll 1993 0/18 1/17 9.2 % 0.30 [ 0.01, 7.81 ]
Total (95% CI) 64 58 100.0 % 0.62 [ 0.23, 1.68 ]
Total events: 11 (Longer course), 14 (Shorter course)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.26, df = 2 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 0.93 (P = 0.35)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours longer Favours shorter
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Analysis 1.6. Comparison 1 Adults: higher dose/longer course vs lower dose/shorter course, Outcome 6
Lung function tests: trough PEFR.
Review: Different oral corticosteroid regimens for acute asthma
Comparison: 1 Adults: higher dose/longer course vs lower dose/shorter course
Outcome: 6 Lung function tests: trough PEFR
Study or subgroup Longer/stable course
Shorter/tapered
course
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Longer vs shorter prednisolone (trough PEFR)
Jones 2002 (1) 24 398 (103) 20 383 (90) 51.7 % 15.00 [ -42.04, 72.04 ]
O Driscoll 1993 18 386 (89.0083) 17 412 (89.0083) 48.3 % -26.00 [ -85.00, 33.00 ]
Subtotal (95% CI) 42 37 100.0 % -4.81 [ -45.82, 36.20 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.96, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 0.23 (P = 0.82)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours shorter Favours longer
(1) Mean trough (waking) PEFR at 21 days
Analysis 1.7. Comparison 1 Adults: higher dose/longer course vs lower dose/shorter course, Outcome 7
Lung function tests: FEV1% predicted.
Review: Different oral corticosteroid regimens for acute asthma
Comparison: 1 Adults: higher dose/longer course vs lower dose/shorter course
Outcome: 7 Lung function tests: FEV1% predicted
Study or subgroup Stable Tapered
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Stable vs tapered prednisolone (FEV1% predicted)
Cydulka 1998 (1) 7 70 (7) 8 67.5 (17.7) 7.3 % 2.50 [ -10.82, 15.82 ]
Karan 2002 (2) 13 71.2 (5.2) 13 72.5 (4.5) 92.7 % -1.30 [ -5.04, 2.44 ]
Subtotal (95% CI) 20 21 100.0 % -1.02 [ -4.62, 2.58 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.29, df = 1 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 0.56 (P = 0.58)
-10 -5 0 5 10
Favours tapered Favours stable
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(1) FEV1% predicted at 21 days (timing of test not stated)
(2) FEV1% predicted at 21 days (timing of test not stated)
Analysis 1.8. Comparison 1 Adults: higher dose/longer course vs lower dose/shorter course, Outcome 8
Lung function tests: number of participants achieving personal best at 4 weeks.
Review: Different oral corticosteroid regimens for acute asthma
Comparison: 1 Adults: higher dose/longer course vs lower dose/shorter course
Outcome: 8 Lung function tests: number of participants achieving personal best at 4 weeks
Study or subgroup Longer course Shorter course Odds Ratio Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Longer vs shorter course prednisolone
Hasegawa 2000 (1) 6/10 5/10 1.50 [ 0.26, 8.82 ]
0.005 0.1 1 10 200
Favours shorter Favours longer
(1) Number of patients achieving personal best PEFR at 4 weeks
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Analysis 1.9. Comparison 1 Adults: higher dose/longer course vs lower dose/shorter course, Outcome 9 All
adverse events.
Review: Different oral corticosteroid regimens for acute asthma
Comparison: 1 Adults: higher dose/longer course vs lower dose/shorter course
Outcome: 9 All adverse events
Study or subgroup Longer course Shorter course Odds Ratio Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Longer vs shorter course prednisolone
Lederle 1987 (1) 9/22 3/21 4.15 [ 0.94, 18.41 ]
0.01 0.1 1 10 100
Favours longer Favours shorter
(1) Patients with ’steroid side effects’ (including weight gain, oedema, acne and easy bruising)
Analysis 2.1. Comparison 2 Adults: prednisolone vs dexamethasone, Outcome 1 Re-admission during
follow-up period.
Review: Different oral corticosteroid regimens for acute asthma
Comparison: 2 Adults: prednisolone vs dexamethasone
Outcome: 1 Re-admission during follow-up period
Study or subgroup Prednisolone Dexamethasone Odds Ratio Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Kravitz 2011 1/96 3/104 0.35 [ 0.04, 3.47 ]
0.001 0.01 0.1 1 10 100 1000
Favours predisolone Favours dexamethasone
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Analysis 2.2. Comparison 2 Adults: prednisolone vs dexamethasone, Outcome 2 Asthma symptoms:
returned to normal activities within 3 days.
Review: Different oral corticosteroid regimens for acute asthma
Comparison: 2 Adults: prednisolone vs dexamethasone
Outcome: 2 Asthma symptoms: returned to normal activities within 3 days
Study or subgroup Prednisolone Dexamethasone Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Kravitz 2011 72/90 91/101 100.0 % 0.44 [ 0.19, 1.01 ]
Total (95% CI) 90 101 100.0 % 0.44 [ 0.19, 1.01 ]
Total events: 72 (Prednisolone), 91 (Dexamethasone)
Heterogeneity: not applicable
Test for overall effect: Z = 1.94 (P = 0.053)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours dexamethasone Favours prednisolone
Analysis 2.3. Comparison 2 Adults: prednisolone vs dexamethasone, Outcome 3 New exacerbation during
follow-up period: any ED visit after discharge.
Review: Different oral corticosteroid regimens for acute asthma
Comparison: 2 Adults: prednisolone vs dexamethasone
Outcome: 3 New exacerbation during follow-up period: any ED visit after discharge
Study or subgroup Prednisolone Dexamethasone Odds Ratio Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Kravitz 2011 6/96 5/104 1.32 [ 0.39, 4.47 ]
0.01 0.1 1 10 100
Favours prednisolone Favours dexamethasone
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Analysis 2.4. Comparison 2 Adults: prednisolone vs dexamethasone, Outcome 4 New exacerbation during
follow-up period: unscheduled visit to primary healthcare provider.
Review: Different oral corticosteroid regimens for acute asthma
Comparison: 2 Adults: prednisolone vs dexamethasone
Outcome: 4 New exacerbation during follow-up period: unscheduled visit to primary healthcare provider
Study or subgroup Prednisolone Dexamethasone Odds Ratio Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Kravitz 2011 5/96 3/104 1.85 [ 0.43, 7.96 ]
0.01 0.1 1 10 100
Favours prednisolone Favours dexamethasone
Analysis 3.1. Comparison 3 Children: higher dose/longer course vs lower dose/shorter course, Outcome 1
Admission at initial presentation.
Review: Different oral corticosteroid regimens for acute asthma
Comparison: 3 Children: higher dose/longer course vs lower dose/shorter course
Outcome: 1 Admission at initial presentation
Study or subgroup Longer course Shorter course Odds Ratio Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Longer vs shorter course dexamethasone
Ghafouri 2010 11/63 7/62 1.66 [ 0.60, 4.61 ]
0.01 0.1 1 10 100
Favours longer Favours shorter
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Analysis 3.2. Comparison 3 Children: higher dose/longer course vs lower dose/shorter course, Outcome 2
Re-admission during follow-up period.
Review: Different oral corticosteroid regimens for acute asthma
Comparison: 3 Children: higher dose/longer course vs lower dose/shorter course
Outcome: 2 Re-admission during follow-up period
Study or subgroup Higher/longer dose Lower/sohrter dose Odds Ratio Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Higher-dose vs lower-dose prednisolone
Kayani 2002 (1) 0/43 0/43 Not estimable
Langton Hewer 1998 (2) 2/30 3/68 1.55 [ 0.24, 9.78 ]
NCT00257933 (3) 0/72 0/73 Not estimable
2 Longer vs shorter course prednisolone
Chang 2008 (4) 0/100 1/101 0.33 [ 0.01, 8.28 ]
3 Longer vs shorter course dexamethasone
Ghafouri 2010 (5) 2/48 1/52 2.22 [ 0.19, 25.27 ]
0.005 0.1 1 10 200
Favours higher/longer Favours lower/shorter
(1) Within 2 weeks of initial presentation
(2) Two lower dose treatment arms pooled; total n randomised used
(3) Within 2 weeks of initial presentation
(4) Re-admission within 2 weeks of presentation
(5) Re-admission in 7 days after initial presentation
83Different oral corticosteroid regimens for acute asthma (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.3. Comparison 3 Children: higher dose/longer course vs lower dose/shorter course, Outcome 3
Asthma symptoms: clinical asthma score at discharge.
Review: Different oral corticosteroid regimens for acute asthma
Comparison: 3 Children: higher dose/longer course vs lower dose/shorter course
Outcome: 3 Asthma symptoms: clinical asthma score at discharge
Study or subgroup Higher dose Lower dose
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High vs medium dose
Langton Hewer 1998 23 3.3 (1.6785) 29 2.6 (1.2924) 0.70 [ -0.13, 1.53 ]
2 High vs low dose
Langton Hewer 1998 23 3.3 (1.6785) 31 2.4 (1.3363) 0.90 [ 0.07, 1.73 ]
3 Medium vs low dose
Langton Hewer 1998 29 2.6 (1.2924) 31 2.4 (1.3363) 0.20 [ -0.47, 0.87 ]
-4 -2 0 2 4
Favours higher Favours lower
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Analysis 3.4. Comparison 3 Children: higher dose/longer course vs lower dose/shorter course, Outcome 4
Asthma symptoms: symptom free by 7 days.
Review: Different oral corticosteroid regimens for acute asthma
Comparison: 3 Children: higher dose/longer course vs lower dose/shorter course
Outcome: 4 Asthma symptoms: symptom free by 7 days
Study or subgroup Longer course Shorter course Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Longer vs shorter course prednisolone
Chang 2008 35/100 31/101 100.0 % 1.22 [ 0.67, 2.19 ]
Total (95% CI) 100 101 100.0 % 1.22 [ 0.67, 2.19 ]
Total events: 35 (Longer course), 31 (Shorter course)
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.52)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours shorter Favours longer
Analysis 3.5. Comparison 3 Children: higher dose/longer course vs lower dose/shorter course, Outcome 5
Serious adverse events.
Review: Different oral corticosteroid regimens for acute asthma
Comparison: 3 Children: higher dose/longer course vs lower dose/shorter course
Outcome: 5 Serious adverse events
Study or subgroup Longer course Shorter course Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Longer vs shorter course prednisolone
Chang 2008 0/100 0/101 Not estimable
Total (95% CI) 100 101 Not estimable
Total events: 0 (Longer course), 0 (Shorter course)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 0.0, df = -1 (P = 0.0), I2 =0.0%
0.01 0.1 1 10 100
Favours longer Favours shorter
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Analysis 3.6. Comparison 3 Children: higher dose/longer course vs lower dose/shorter course, Outcome 6
New exacerbation during follow-up period: oral corticosteroids prescribed.
Review: Different oral corticosteroid regimens for acute asthma
Comparison: 3 Children: higher dose/longer course vs lower dose/shorter course
Outcome: 6 New exacerbation during follow-up period: oral corticosteroids prescribed
Study or subgroup Higher/longer dose Lower/shorter dose Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Higher-dose vs lower-dose prednisolone
Kayani 2002 (1) 1/43 0/43 27.5 % 3.07 [ 0.12, 77.50 ]
NCT00257933 2/72 2/73 72.5 % 1.01 [ 0.14, 7.40 ]
Subtotal (95% CI) 115 116 100.0 % 1.38 [ 0.25, 7.47 ]
Total events: 3 (Higher/longer dose), 2 (Lower/shorter dose)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.33, df = 1 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 0.37 (P = 0.71)
2 Longer vs shorter course prednisolone
Chang 2008 (2) 5/100 8/101 100.0 % 0.61 [ 0.19, 1.94 ]
Subtotal (95% CI) 100 101 100.0 % 0.61 [ 0.19, 1.94 ]
Total events: 5 (Higher/longer dose), 8 (Lower/shorter dose)
Heterogeneity: not applicable
Test for overall effect: Z = 0.83 (P = 0.40)
3 Longer vs shorter course dexamethasone
Ghafouri 2010 2/48 8/52 100.0 % 0.24 [ 0.05, 1.19 ]
Subtotal (95% CI) 48 52 100.0 % 0.24 [ 0.05, 1.19 ]
Total events: 2 (Higher/longer dose), 8 (Lower/shorter dose)
Heterogeneity: not applicable
Test for overall effect: Z = 1.75 (P = 0.080)
Test for subgroup differences: Chi2 = 2.18, df = 2 (P = 0.34), I2 =8%
0.01 0.1 1 10 100
Favours higher/longer Favours lower/shorter
(1) Within 2 weeks of initial presentation
(2) ”Received additional prednisolone in follow up period”
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Analysis 3.7. Comparison 3 Children: higher dose/longer course vs lower dose/shorter course, Outcome 7
New exacerbation during follow-up period: unscheduled visit to healthcare provider.
Review: Different oral corticosteroid regimens for acute asthma
Comparison: 3 Children: higher dose/longer course vs lower dose/shorter course
Outcome: 7 New exacerbation during follow-up period: unscheduled visit to healthcare provider
Study or subgroup Longer course Shorter course Odds Ratio Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Longer vs shorter course dexamethasone
Ghafouri 2010 (1) 9/48 5/52 2.17 [ 0.67, 7.01 ]
0.01 0.1 1 10 100
Favours longer Favours shorter
(1) Defined as unscheduled follow up with health care provider after discharge until day 7
Analysis 3.8. Comparison 3 Children: higher dose/longer course vs lower dose/shorter course, Outcome 8
Lung function tests: FEV1% predicted at discharge.
Review: Different oral corticosteroid regimens for acute asthma
Comparison: 3 Children: higher dose/longer course vs lower dose/shorter course
Outcome: 8 Lung function tests: FEV1% predicted at discharge
Study or subgroup Higher dose Lower dose
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High vs medium dose
Langton Hewer 1998 8 79.9 (18.4413) 11 65.8 (23.0505) 14.10 [ -4.58, 32.78 ]
2 High vs low dose
Langton Hewer 1998 8 79.9 (18.4413) 15 77.1 (22.1535) 2.80 [ -14.20, 19.80 ]
3 Medium vs low dose
Langton Hewer 1998 11 65.8 (23.0505) 15 77.1 (22.1535) -11.30 [ -28.94, 6.34 ]
-100 -50 0 50 100
Favours lower Favours higher
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Analysis 3.9. Comparison 3 Children: higher dose/longer course vs lower dose/shorter course, Outcome 9
Lung function tests: PEFR% predicted at discharge.
Review: Different oral corticosteroid regimens for acute asthma
Comparison: 3 Children: higher dose/longer course vs lower dose/shorter course
Outcome: 9 Lung function tests: PEFR% predicted at discharge
Study or subgroup Higher dose Lower dose
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High vs medium dose
Langton Hewer 1998 8 116.6 (24.3245) 11 88.7 (24.9079) 27.90 [ 5.52, 50.28 ]
2 High vs low dose
Langton Hewer 1998 8 116.6 (24.3245) 15 99.4 (33.0365) 17.20 [ -6.54, 40.94 ]
3 Medium vs low dose
Langton Hewer 1998 11 88.7 (24.9079) 15 99.4 (33.0365) -10.70 [ -32.97, 11.57 ]
-100 -50 0 50 100
Favours lower Favours higher
Analysis 3.10. Comparison 3 Children: higher dose/longer course vs lower dose/shorter course, Outcome
10 All adverse events: longer vs short course prednisolone.
Review: Different oral corticosteroid regimens for acute asthma
Comparison: 3 Children: higher dose/longer course vs lower dose/shorter course
Outcome: 10 All adverse events: longer vs short course prednisolone
Study or subgroup Longer course Shorter course Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Chang 2008 2/100 3/101 100.0 % 0.67 [ 0.11, 4.08 ]
Total (95% CI) 100 101 100.0 % 0.67 [ 0.11, 4.08 ]
Total events: 2 (Longer course), 3 (Shorter course)
Heterogeneity: not applicable
Test for overall effect: Z = 0.44 (P = 0.66)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours longer course Favours shorter course
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Analysis 3.11. Comparison 3 Children: higher dose/longer course vs lower dose/shorter course, Outcome
11 All adverse events: higher-dose vs lower-dose prednisolone.
Review: Different oral corticosteroid regimens for acute asthma
Comparison: 3 Children: higher dose/longer course vs lower dose/shorter course
Outcome: 11 All adverse events: higher-dose vs lower-dose prednisolone
Study or subgroup Higher dose Lower dose Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Facial fullness
Kayani 2002 6/43 6/43 41.4 % 1.00 [ 0.30, 3.39 ]
NCT00257933 10/72 7/73 58.6 % 1.52 [ 0.54, 4.24 ]
Subtotal (95% CI) 115 116 100.0 % 1.28 [ 0.58, 2.80 ]
Total events: 16 (Higher dose), 13 (Lower dose)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.27, df = 1 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 0.61 (P = 0.54)
2 Facial erythema
Kayani 2002 7/43 6/43 59.2 % 1.20 [ 0.37, 3.91 ]
NCT00257933 3/72 6/73 40.8 % 0.49 [ 0.12, 2.02 ]
Subtotal (95% CI) 115 116 100.0 % 0.83 [ 0.33, 2.06 ]
Total events: 10 (Higher dose), 12 (Lower dose)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.92, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 0.40 (P = 0.69)
3 Change in appetite
Kayani 2002 5/43 5/43 22.9 % 1.00 [ 0.27, 3.74 ]
NCT00257933 20/72 22/73 77.1 % 0.89 [ 0.43, 1.83 ]
Subtotal (95% CI) 115 116 100.0 % 0.92 [ 0.49, 1.72 ]
Total events: 25 (Higher dose), 27 (Lower dose)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 0.27 (P = 0.78)
4 Abdominal pain
Kayani 2002 3/43 2/43 22.5 % 1.54 [ 0.24, 9.69 ]
NCT00257933 10/72 8/73 77.5 % 1.31 [ 0.49, 3.54 ]
Subtotal (95% CI) 115 116 100.0 % 1.36 [ 0.57, 3.25 ]
0.001 0.01 0.1 1 10 100 1000
Favours higher dose Favours lower dose
(Continued . . . )
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(. . . Continued)
Study or subgroup Higher dose Lower dose Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 13 (Higher dose), 10 (Lower dose)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 0.69 (P = 0.49)
5 Diarrhoea
Kayani 2002 1/43 1/43 38.4 % 1.00 [ 0.06, 16.52 ]
NCT00257933 4/72 1/73 61.6 % 4.24 [ 0.46, 38.85 ]
Subtotal (95% CI) 115 116 100.0 % 2.43 [ 0.43, 13.84 ]
Total events: 5 (Higher dose), 2 (Lower dose)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.63, df = 1 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 1.00 (P = 0.32)
6 Anxiety
Kayani 2002 9/43 2/43 49.0 % 5.43 [ 1.10, 26.83 ]
NCT00257933 3/72 5/73 51.0 % 0.59 [ 0.14, 2.57 ]
Subtotal (95% CI) 115 116 100.0 % 1.75 [ 0.20, 15.49 ]
Total events: 12 (Higher dose), 7 (Lower dose)
Heterogeneity: Tau2 = 1.86; Chi2 = 4.03, df = 1 (P = 0.04); I2 =75%
Test for overall effect: Z = 0.50 (P = 0.61)
7 Euphoria
Kayani 2002 2/43 2/43 23.5 % 1.00 [ 0.13, 7.44 ]
NCT00257933 6/72 8/73 76.5 % 0.74 [ 0.24, 2.25 ]
Subtotal (95% CI) 115 116 100.0 % 0.79 [ 0.30, 2.10 ]
Total events: 8 (Higher dose), 10 (Lower dose)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.07, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.47 (P = 0.64)
8 Depression
Kayani 2002 0/43 2/43 15.4 % 0.19 [ 0.01, 4.09 ]
NCT00257933 4/73 6/73 84.6 % 0.65 [ 0.17, 2.40 ]
Subtotal (95% CI) 116 116 100.0 % 0.54 [ 0.16, 1.79 ]
Total events: 4 (Higher dose), 8 (Lower dose)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.52, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 1.01 (P = 0.31)
9 Quiet and reserved
Kayani 2002 3/43 2/43 25.2 % 1.54 [ 0.24, 9.69 ]
NCT00257933 10/72 6/73 74.8 % 1.80 [ 0.62, 5.25 ]
Subtotal (95% CI) 115 116 100.0 % 1.73 [ 0.69, 4.36 ]
Total events: 13 (Higher dose), 8 (Lower dose)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 1.16 (P = 0.25)
10 Hyperactive
0.001 0.01 0.1 1 10 100 1000
Favours higher dose Favours lower dose
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(. . . Continued)
Study or subgroup Higher dose Lower dose Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Kayani 2002 9/43 4/43 28.4 % 2.58 [ 0.73, 9.14 ]
Langton Hewer 1998 (1) 6/24 17/63 32.1 % 0.90 [ 0.31, 2.65 ]
NCT00257933 16/72 30/73 39.5 % 0.41 [ 0.20, 0.85 ]
Subtotal (95% CI) 139 179 100.0 % 0.89 [ 0.31, 2.52 ]
Total events: 31 (Higher dose), 51 (Lower dose)
Heterogeneity: Tau2 = 0.58; Chi2 = 6.41, df = 2 (P = 0.04); I2 =69%
Test for overall effect: Z = 0.22 (P = 0.83)
11 Aggressive behaviour
Kayani 2002 9/43 0/43 46.4 % 23.96 [ 1.35, 426.22 ]
NCT00257933 4/72 14/73 53.6 % 0.25 [ 0.08, 0.79 ]
Subtotal (95% CI) 115 116 100.0 % 2.06 [ 0.02, 267.49 ]
Total events: 13 (Higher dose), 14 (Lower dose)
Heterogeneity: Tau2 = 11.13; Chi2 = 9.87, df = 1 (P = 0.002); I2 =90%
Test for overall effect: Z = 0.29 (P = 0.77)
0.001 0.01 0.1 1 10 100 1000
Favours higher dose Favours lower dose
(1) Two lower dose intervention arms pooled; n completed used
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Analysis 4.1. Comparison 4 Children: prednisolone vs dexamethasone, Outcome 1 Admission at initial
presentation.
Review: Different oral corticosteroid regimens for acute asthma
Comparison: 4 Children: prednisolone vs dexamethasone
Outcome: 1 Admission at initial presentation
Study or subgroup Prednisolone Dexamethasone Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Altamimi 2006 9/67 6/67 12.2 % 1.58 [ 0.53, 4.71 ]
Cronin 2015 16/122 18/123 27.6 % 0.88 [ 0.43, 1.82 ]
Qureshi 2001 38/319 34/309 60.2 % 1.09 [ 0.67, 1.79 ]
Total (95% CI) 508 499 100.0 % 1.08 [ 0.74, 1.58 ]
Total events: 63 (Prednisolone), 58 (Dexamethasone)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.77, df = 2 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 0.38 (P = 0.70)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours prednisolone Favours dexamethasone
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Analysis 4.2. Comparison 4 Children: prednisolone vs dexamethasone, Outcome 2 Re-admission during
follow-up period.
Review: Different oral corticosteroid regimens for acute asthma
Comparison: 4 Children: prednisolone vs dexamethasone
Outcome: 2 Re-admission during follow-up period
Study or subgroup Prednisolone Dexamethasone Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Altamimi 2006 1/54 3/56 23.0 % 0.33 [ 0.03, 3.31 ]
Cronin 2015 1/120 3/122 23.4 % 0.33 [ 0.03, 3.25 ]
Qureshi 2001 (1) 3/361 4/272 53.6 % 0.56 [ 0.12, 2.53 ]
Total (95% CI) 535 450 100.0 % 0.44 [ 0.15, 1.33 ]
Total events: 5 (Prednisolone), 10 (Dexamethasone)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.22, df = 2 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 1.46 (P = 0.14)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours prednisolone Favours dexamethasone
(1) Number who were admitted after a relapse; we assume that no-one who did not relapse was admitted
Analysis 4.3. Comparison 4 Children: prednisolone vs dexamethasone, Outcome 3 Asthma symptoms: PIS.
Review: Different oral corticosteroid regimens for acute asthma
Comparison: 4 Children: prednisolone vs dexamethasone
Outcome: 3 Asthma symptoms: PIS
Study or subgroup Prednisolone Dexamethasone
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Altamimi 2006 (1) 54 0.3 (1.06) 56 0.4 (0.8) 100.0 % -0.10 [ -0.45, 0.25 ]
Total (95% CI) 54 56 100.0 % -0.10 [ -0.45, 0.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.58)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours prednisolone Favours dexamethasone
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(1) Pulmonary index score at day 5
Analysis 4.4. Comparison 4 Children: prednisolone vs dexamethasone, Outcome 4 Asthma symptoms:
PSAS.
Review: Different oral corticosteroid regimens for acute asthma
Comparison: 4 Children: prednisolone vs dexamethasone
Outcome: 4 Asthma symptoms: PSAS
Study or subgroup Prednisolone Dexamethasone
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Altamimi 2006 (1) 54 5.22 (1.71) 56 5.21 (1.94) 100.0 % 0.01 [ -0.67, 0.69 ]
Total (95% CI) 54 56 100.0 % 0.01 [ -0.67, 0.69 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.98)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours prednisolone Favours dexamethasone
(1) Mean no. of days for PSAS (patient self assessment sheet) to return to normal (0-0.5)
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Analysis 4.5. Comparison 4 Children: prednisolone vs dexamethasone, Outcome 5 Asthma symptoms:
PRAM.
Review: Different oral corticosteroid regimens for acute asthma
Comparison: 4 Children: prednisolone vs dexamethasone
Outcome: 5 Asthma symptoms: PRAM
Study or subgroup Prednisolone Dexamethasone
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Cronin 2015 (1) 108 0.92 (1.55) 110 0.92 (1.15) 100.0 % 0.0 [ -0.36, 0.36 ]
Total (95% CI) 108 110 100.0 % 0.0 [ -0.36, 0.36 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
-0.5 -0.25 0 0.25 0.5
Favours prednisolone Favours dexamethasone
(1) We extracted the result which excluded re-enrolments
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Analysis 4.6. Comparison 4 Children: prednisolone vs dexamethasone, Outcome 6 Asthma symptoms.
Review: Different oral corticosteroid regimens for acute asthma
Comparison: 4 Children: prednisolone vs dexamethasone
Outcome: 6 Asthma symptoms
Study or subgroup Prednisolone Dexamethasone Odds Ratio Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Persistent cough
Qureshi 2001 48/261 57/272 0.85 [ 0.55, 1.30 ]
2 Wheeze
Qureshi 2001 30/261 32/272 0.97 [ 0.57, 1.65 ]
3 Tightness of chest
Qureshi 2001 11/261 11/272 1.04 [ 0.44, 2.45 ]
4 Night wakening
Qureshi 2001 16/261 13/272 1.30 [ 0.61, 2.76 ]
5 Difficulty maintaining normal activities
Qureshi 2001 18/261 14/272 1.37 [ 0.66, 2.80 ]
0.5 0.7 1 1.5 2
Favours prednisolone Favours dexamethasone
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Analysis 4.7. Comparison 4 Children: prednisolone vs dexamethasone, Outcome 7 Serious adverse events.
Review: Different oral corticosteroid regimens for acute asthma
Comparison: 4 Children: prednisolone vs dexamethasone
Outcome: 7 Serious adverse events
Study or subgroup Prednisolone Dexamethasone Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Altamimi 2006 (1) 0/54 0/56 Not estimable
Qureshi 2001 0/72 0/73 Not estimable
Total (95% CI) 126 129 Not estimable
Total events: 0 (Prednisolone), 0 (Dexamethasone)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours prednisolone Favours dexamethasone
(1) ”Significant side effects”
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Analysis 4.8. Comparison 4 Children: prednisolone vs dexamethasone, Outcome 8 New exacerbation
during follow-up period: unscheduled visit to healthcare provider.
Review: Different oral corticosteroid regimens for acute asthma
Comparison: 4 Children: prednisolone vs dexamethasone
Outcome: 8 New exacerbation during follow-up period: unscheduled visit to healthcare provider
Study or subgroup Prednisolone Dexamethasone Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Altamimi 2006 (1) 1/56 4/61 4.1 % 0.26 [ 0.03, 2.39 ]
Cronin 2015 (2) 17/120 17/122 38.8 % 1.02 [ 0.49, 2.11 ]
Greenberg 2008 (3) 3/38 8/51 10.4 % 0.46 [ 0.11, 1.87 ]
Qureshi 2001 18/261 20/272 46.7 % 0.93 [ 0.48, 1.81 ]
Total (95% CI) 475 506 100.0 % 0.85 [ 0.54, 1.34 ]
Total events: 39 (Prednisolone), 49 (Dexamethasone)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.16, df = 3 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.70 (P = 0.48)
Test for subgroup differences: Not applicable
0.02 0.1 1 10 50
Favours prednisolone Favours dexamethasone
(1) Defined as an unscheduled return to the ED
(2) Return visit to health care provider within 14 days
(3) Defined as unscheduled follow up with health care provider with 10 days
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Analysis 4.9. Comparison 4 Children: prednisolone vs dexamethasone, Outcome 9 New exacerbation
during follow-up period: oral corticosteroids prescribed.
Review: Different oral corticosteroid regimens for acute asthma
Comparison: 4 Children: prednisolone vs dexamethasone
Outcome: 9 New exacerbation during follow-up period: oral corticosteroids prescribed
Study or subgroup Prednisolone Dexamethasone Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Cronin 2015 5/120 16/122 100.0 % 0.29 [ 0.10, 0.81 ]
Total (95% CI) 120 122 100.0 % 0.29 [ 0.10, 0.81 ]
Total events: 5 (Prednisolone), 16 (Dexamethasone)
Heterogeneity: not applicable
Test for overall effect: Z = 2.35 (P = 0.019)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours prednisolone Favours dexamethasone
Analysis 4.10. Comparison 4 Children: prednisolone vs dexamethasone, Outcome 10 Adverse event:
vomiting.
Review: Different oral corticosteroid regimens for acute asthma
Comparison: 4 Children: prednisolone vs dexamethasone
Outcome: 10 Adverse event: vomiting
Study or subgroup Prednisolone Dexamethasone Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Cronin 2015 (1) 14/122 0/123 14.9 % 33.01 [ 1.95, 559.90 ]
Greenberg 2008 (2) 7/38 5/51 39.6 % 2.08 [ 0.60, 7.14 ]
Qureshi 2001 (3) 11/261 6/272 45.5 % 1.95 [ 0.71, 5.35 ]
Total (95% CI) 421 446 100.0 % 3.05 [ 0.88, 10.55 ]
Total events: 32 (Prednisolone), 11 (Dexamethasone)
Heterogeneity: Tau2 = 0.62; Chi2 = 4.29, df = 2 (P = 0.12); I2 =53%
Test for overall effect: Z = 1.76 (P = 0.079)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours prednisolone Favours dexamethasone
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(1) Vomiting once or more after any dose
(2) Vomiting after initial dose of steroids
(3) Medication vomited at home
A D D I T I O N A L T A B L E S
Table 1. Summary of included study characteristics
Study ID Total n Country Age range, years Duration of follow-
up
Comparison Total dose compar-
ison (converted to
prednisolone equiv-
alent)
Aboeed 2014 58 USA Not reported 4 weeks Prednisone 40 mg
once daily for 5 days
vs dexamethasone 16
mg once daily for 2
days
200 mg vs 213 mg
Altamimi 2006 134 Canada 2 to16 3 weeks (maximum) Predisolone 1 mg/kg
twice daily for 5 days
vs dexamethasone 0.6
mg/kg once daily for
1 day
200 mg vs 80 mg
(based on 20 kg child)
Chang 2008 201 Australia 2 to15 4 weeks Prednisolone 1mg/kg
daily for 5 days vs
prednisolone 1mg/kg
daily for 3 days
100 mg vs 60 mg
(based on 20 kg child)
Cronin 2015 226 Ireland 2 to 16 2 weeks Prednisolone 1mg/kg
daily for 3 days vs 0.
3 mg/kg dexametha-
sone once daily for 1
day
60 mg vs 40 mg
(based on 20 kg child)
Cydulka 1998 15 USA 19 to 50 3 weeks Prednisolone 40 mg
daily for 8 days vs
prednisolone 40 mg
daily tapering by 5mg
per day for 8 days
320 mg vs 180 mg
Ghafouri 2010 125 USA 2 to 17 1 week Dexamethasone 0.6
mg/kg once daily for
2 doses (days 1 and
160 mg vs 80 mg
(based on 20 kg child)
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Table 1. Summary of included study characteristics (Continued)
3) versus dexametha-
sone 0.6 mg/kg once
daily for 1 day
Greenberg 2008 167 USA 2 to 18 1.5 weeks Prednisolone 1mg/kg
twice daily for 5 days
vs dexamethasone 0.6
mg/kg once daily for
2 days
200 mg vs 160 mg
(based on 20 kg child)
Hasegawa 2000 20 Japan Not reported 26 weeks Prednisolone 0.5 mg/
kg daily for 14 days vs
prednisolone 0.5 mg/
kg once daily for 7
days
490 mg vs 245 mg
(based on70kg adult)
Jones 2002 47 UK 16 to 60 4-6 weeks Prednisolone 40 mg
once daily for 10 days
vs prednisolone 40
mg once daily for 5
days
400 mg vs 200 mg
Karan 2002 26 India 17 to 70 3 weeks Prednisolone 40 mg
daily for 8 days vs
prednisolone 40 mg
daily tapering by 5mg
per day for 8 days
320 mg vs 180 mg
Kayani 2002 88 USA 2 to 18 4 weeks (maximum) Prednisolone 2mg/kg
daily for 5 days vs
prednisolone 1mg/kg
daily for 5 days
200 mg vs 100 mg
(based on 20 kg child)
Kravitz 2011 285 USA 18 to 45 2 weeks Prednisolone 50 mg
once daily for 5 days
vs dexamethasone 16
mg once daily for 2
days
250 mg vs 213 mg
Langton Hewer
1998
98 UK 1 to 15 2 weeks Prednisolone 2mg/kg
once
daily vs prednisolone
1 mg/kg once daily vs
prednisolone 0.5 mg/
kg once daily while
inpatient and for up
to 3 days post dis-
charge
200 mg vs 100 mg vs
50 mg (based on 20
kg child receiving a 5-
day course)
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Table 1. Summary of included study characteristics (Continued)
Lederle 1987 43 USA 30 to 78 12 weeks Prednisolone 45 mg
daily reducing to 0
mg daily over 7 weeks
vs prednisolone 45
mg daily reducing to
0 mg daily over 7 days
1575 mg vs 225 mg
NCT00257933 152 USA 2 to 18 2 weeks Prednisolone 4mg/kg
daily for 2 days, then
2 mg/kg daily for du-
ration of admission vs
prednisolone 2mg/kg
daily for duration of
admission
400 mg vs
200 mg (based on 20
kg child receiving a 5-
day course)
O’Driscoll 1993 39 UK 16 to 55 4-6 weeks Prednisolone 40 mg
daily for 10 days fol-
lowed by 7-day ta-
per vs prednisolone
40 mg daily for 10
days
540 mg vs 400 mg
Qureshi 2001 628 USA 2 to 18 2 weeks Prednisolone 2mg/kg
initial dose, then 1
mg/kg daily for 5 days
vs dexamethasone 0.6
mg/kg once daily for
2 days
120 mg vs 160 mg
(based on 20 kg child)
Viska 2008 86 Indonesia “Adults” 6 weeks Prednisolone 36 mg
daily for 2 weeks vs
prednisolone 12 mg
daily for 2 weeks
504 mg vs 168 mg
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A P P E N D I C E S
Appendix 1. Sources and search methods for the Cochrane Airways Group Specialised Register
(CAGR)
Electronic searches: core databases
Database Frequency of search
CENTRAL (The Cochrane Library) Monthly
MEDLINE (Ovid) Weekly
EMBASE (Ovid) Weekly
PsycINFO (Ovid) Monthly
CINAHL (EBSCO) Monthly
AMED (EBSCO) Monthly
Handsearches: core respiratory conference abstracts
Conference Years searched
AmericanAcademyofAllergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Pacific Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International PrimaryCareRespiratoryGroupCongress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards
MEDLINE search strategy used to identify trials for the CAGR
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Asthma search
1. exp Asthma/
2. asthma$.mp.
3. (antiasthma$ or anti-asthma$).mp.
4. Respiratory Sounds/
5. wheez$.mp.
6. Bronchial Spasm/
7. bronchospas$.mp.
8. (bronch$ adj3 spasm$).mp.
9. bronchoconstrict$.mp.
10. exp Bronchoconstriction/
11. (bronch$ adj3 constrict$).mp.
12. Bronchial Hyperreactivity/
13. Respiratory Hypersensitivity/
14. ((bronchial$ or respiratory or airway$ or lung$) adj3 (hypersensitiv$ or hyperreactiv$ or allerg$ or insufficiency)).mp.
15. ((dust or mite$) adj3 (allerg$ or hypersensitiv$)).mp.
16. or/1-15
Filter to identify RCTs
1. exp “clinical trial [publication type]”/
2. (randomized or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. Animals/
10. Humans/
11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and RCT filter are adapted to identify trials in other electronic databases.
Appendix 2. Search strategy to identify relevant trials from the CAGR
#1 AST:MISC1
#2 MeSH DESCRIPTOR Asthma Explode All
#3 asthma*:ti,ab
#4 #1 or #2 or #3
#5 (systemic* OR oral*) NEAR (steroid* or corticosteroid* or glucocorticoid)
#6 dexamethasone or decadron or prednisolone or pediapred or prednisone or sterapred or hydrocortisone or methylprenisolone or
solucortef or solu-cortef or solumedrol or solu-medrol or betamethasone
#7 #5 or #6
#8 emergenc* or acute* or status or sever* or attack or crisis OR exacerbat* or critical
#9 #4 and #7 and #8
[Note: in search line #1, MISC1 denotes the field in the record in which the reference has been coded for condition, in this case, asthma]
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C O N T R I B U T I O N S O F A U T H O R S
RN drafted the protocol and the review with substantial input, advice and revisions from KMK. RN, GM and KMK screened the
search and extracted data from the included studies. RN entered the data into the review, and KMK performed cross-checks. RN and
KMK contributed to interpretation of the data, and all three authors contributed to the Discussion.
D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• Rebecca Normansell and Kayleigh Kew, Cochrane Airways Group, UK.
Cochrane Airways Group is hosted by the Population Health Research Institute, St George’s, University of London.
External sources
• National Institute of Health Research, UK.
Evidence to guide care in adults and children with asthma, 13/89/14. This project was supported by the National Institute for Health
Research, via Cochrane Infrastructure, Cochrane Programme Grant or Cochrane Incentive funding to Cochrane Airways. The views
and opinions expressed therein are those of the review authors and do not necessarily reflect those of the Systematic Reviews
Programme, NIHR, NHS or the Department of Health.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In a change to our protocol, we did not search manufacturers’ websites, as the intervention medication is made generically by a large
number of manufacturers worldwide. In addition, only one review author (RN) extracted study characteristics from included studies,
and another review author (KMK) independently spot-checked the extracted information for accuracy.
We stated that we would contact study authors to ask for more information when a trial was reported as an abstract only. In a change
to our protocol, we did not contact the authors of Ghafouri 2010, as the trial was prospectively registered and all outcomes were clearly
reported in tables that accompanied the abstract. We contacted the authors of Aboeed 2014, NCT00257933 and Viska 2008 to ask
for additional details.
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